<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome - Ardell, S - 2015 | Cochrane Library</title> <meta content="Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome - Ardell, S - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000144.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome - Ardell, S - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000144.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000144.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome" name="citation_title"/> <meta content="Stephanie Ardell" name="citation_author"/> <meta content="University of Pittsburgh Medical Center" name="citation_author_institution"/> <meta content="Robert H Pfister" name="citation_author"/> <meta content="St Charles Health Care" name="citation_author_institution"/> <meta content="Roger Soll" name="citation_author"/> <meta content="University of Vermont Medical Center" name="citation_author_institution"/> <meta content="Roger.Soll@vtmednet.org" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD000144.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/08/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000144.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000144.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000144.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cerebral Hemorrhage [chemically induced]; Drug Combinations; Enterocolitis, Necrotizing [chemically induced]; Fatty Alcohols [therapeutic use]; Infant, Premature; Polyethylene Glycols [therapeutic use]; Pulmonary Surfactants [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Respiratory Distress Syndrome, Newborn [*drug therapy, *prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000144.pub3&amp;doi=10.1002/14651858.CD000144.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="FKeXZrqu";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000144\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000144\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","th","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000144.pub3",title:"Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome",firstPublishedDate:"Aug 24, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=FKeXZrqu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000144.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000144.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000144.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000144.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000144.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000144.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000144.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000144.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000144.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000144.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5423 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000144.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full#CD000144-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full#CD000144-sec-0106"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full#CD000144-sec-0029"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full#CD000144-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full#CD000144-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full#CD000144-sec-0058"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full#CD000144-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/table_n/CD000144StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/table_n/CD000144StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/information#CD000144-cr-0002">Stephanie Ardell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/information#CD000144-cr-0003">Robert H Pfister</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000144.pub3/information#CD000144-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Roger Soll</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/information/en#CD000144-sec-0114">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 August 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000144.pub3">https://doi.org/10.1002/14651858.CD000144.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000144-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000144-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000144-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000144-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000144-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD000144-abs-0002">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000144-abs-0001" lang="en"> <section id="CD000144-sec-0001"> <h3 class="title" id="CD000144-sec-0001">Background</h3> <p>A wide variety of surfactant preparations have been developed and tested including synthetic surfactants and surfactants derived from animal sources. Although clinical trials have demonstrated that both synthetic surfactant and animal derived surfactant preparations are effective, comparison in animal models has suggested that there may be greater efficacy of animal derived surfactant products, perhaps due to the protein content of animal derived surfactant. </p> </section> <section id="CD000144-sec-0002"> <h3 class="title" id="CD000144-sec-0002">Objectives</h3> <p>To compare the effect of animal derived surfactant to protein free synthetic surfactant preparations in preterm infants at risk for or having respiratory distress syndrome (RDS). </p> </section> <section id="CD000144-sec-0003"> <h3 class="title" id="CD000144-sec-0003">Search methods</h3> <p>Searches were updated of the Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i> (2014), PubMed, CINAHL and EMBASE (1975 through November 2014). All languages were included. </p> </section> <section id="CD000144-sec-0004"> <h3 class="title" id="CD000144-sec-0004">Selection criteria</h3> <p>Randomized controlled trials comparing administration of protein free synthetic surfactants to administration of animal derived surfactant extracts in preterm infants at risk for or having respiratory distress syndrome were considered for this review. </p> </section> <section id="CD000144-sec-0005"> <h3 class="title" id="CD000144-sec-0005">Data collection and analysis</h3> <p>Data collection and analysis were conducted according to the standards of the Cochrane Neonatal Review Group. </p> </section> <section id="CD000144-sec-0006"> <h3 class="title" id="CD000144-sec-0006">Main results</h3> <p>Fifteen trials met the inclusion criteria. The meta‐analysis showed that the use of animal derived surfactant rather than protein free synthetic surfactant resulted in a significant reduction in the risk of pneumothorax [typical relative risk (RR) 0.65, 95% CI 0.55 to 0.77; typical risk difference (RD) ‐0.04, 95% CI ‐0.06 to ‐0.02; number needed to treat to benefit (NNTB) 25; 11 studies, 5356 infants] and a marginal reduction in the risk of mortality (typical RR 0.89, 95% CI 0.79 to 0.99; typical RD ‐0.02, 95% CI ‐0.04 to ‐0.00; NNTB 50; 13 studies, 5413 infants). </p> <p>Animal derived surfactant was associated with an increase in the risk of necrotizing enterocolitis [typical RR 1.38, 95% CI 1.08 to 1.76; typical RD 0.02, 95% CI 0.01 to 0.04; number needed to treat to harm (NNTH) 50; 8 studies, 3462 infants] and a marginal increase in the risk of any intraventricular hemorrhage (typical RR 1.07, 95% CI 0.99 to 1.15; typical RD 0.02, 95% CI 0.00 to 0.05; 10 studies, 5045 infants) but no increase in Grade 3 to 4 intraventricular hemorrhage (typical RR 1.08, 95% CI 0.91 to 1.27; typical RD 0.01, 95% CI ‐0.01 to 0.03; 9 studies, 4241 infants). </p> <p>The meta‐analyses supported a marginal decrease in the risk of bronchopulmonary dysplasia or mortality associated with the use of animal derived surfactant preparations (typical RR 0.95, 95% CI 0.91 to 1.00; typical RD ‐0.03, 95% CI ‐0.06 to 0.00; 6 studies, 3811 infants). No other relevant differences in outcomes were noted. </p> </section> <section id="CD000144-sec-0007"> <h3 class="title" id="CD000144-sec-0007">Authors' conclusions</h3> <p>Both animal derived surfactant extracts and protein free synthetic surfactant extracts are effective in the treatment and prevention of respiratory distress syndrome. Comparative trials demonstrate greater early improvement in the requirement for ventilator support, fewer pneumothoraces, and fewer deaths associated with animal derived surfactant extract treatment. Animal derived surfactant may be associated with an increase in necrotizing enterocolitis and intraventricular hemorrhage, though the more serious hemorrhages (Grade 3 and 4) are not increased. Despite these concerns, animal derived surfactant extracts would seem to be the more desirable choice when compared to currently available protein free synthetic surfactants. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000144-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000144-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000144-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000144-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000144-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000144-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000144-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD000144-abs-0007">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000144-abs-0005" lang="en"> <h3>Animal derived surfactant compared to protein‐free synthetic surfactant preparations in preterm infants that have or are at high risk for respiratory distress syndrome. </h3> <p>Review question: Does the use of animal derived surfactant preparations compared to synthetic surfactant preparations that do not contain protein lead to improved outcome in infants at risk for or having respiratory distress syndrome? </p> <p>Background: Pulmonary surfactant is a substance that prevents the air sacs of the lungs from collapsing by reducing surface tension. Newborn babies with respiratory distress syndrome (RDS) have immature lungs and are often lacking in pulmonary surfactant. Commercially available surfactant preparations (either animal derived surfactant preparations or synthetic surfactant preparations that may or may not contain protein) can be given to these babies and have been proven to decrease the severity of RDS and increase the survival rates of babies with RDS. However, it is unclear whether significant differences in clinical outcome exist among the available animal derived surfactant preparations or the protein‐free synthetic surfactant preparations. </p> <p>Study characteristics: Fifteen randomized controlled trials met our inclusion criteria.</p> <p>Results: This review of trials compared animal derived surfactant extracts with synthetic surfactants that did not contain protein and found a decrease in the risk of pneumothorax (air in the lung cavity) and death in babies receiving animal derived surfactant extracts. </p> <p>Some evidence that animal derived surfactant extract leads to better outcomes in babies with respiratory distress syndrome compared to synthetic surfactants that do not contains proteins. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000144-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000144-sec-0106"></div> <h3 class="title" id="CD000144-sec-0107">Implications for practice</h3> <section id="CD000144-sec-0107"> <p>Both animal derived surfactant extracts and synthetic surfactant extracts are effective in the treatment and prevention of respiratory distress syndrome. Comparative trials demonstrate greater early improvement in the requirement for ventilator support, fewer pneumothoraces, and fewer deaths associated with animal derived surfactant extract treatment. A trend toward improved survival without bronchopulmonary dysplasia is noted. An increase in the risk of necrotizing enterocolitis is seen with animal derived products. In addition, an increase in the risk of intraventricular hemorrhage is seen with animal derived surfactant extract administration but is only reflected in the lesser grades of hemorrhage. On clinical grounds, animal derived surfactant extracts would seem to be the more desirable choice when compared to currently available synthetic surfactants. </p> </section> <h3 class="title" id="CD000144-sec-0108">Implications for research</h3> <section id="CD000144-sec-0108"> <p>Clinical trials that compare newer synthetic surfactants such as lucinactant (KL4) to available animal derived surfactant extracts are needed. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000144-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000144-sec-0029"></div> <section id="CD000144-sec-0030"> <h3 class="title" id="CD000144-sec-0030">Description of the condition</h3> <p>Respiratory distress syndrome (RDS) is primarily a disease of the preterm infant and is due to lung immaturity and a deficiency of endogenous surfactant (<a href="./references#CD000144-bbs2-0040" title="JobeAH . Pulmonary surfactant therapy. New England Journal of Medicine1993;328(12):861‐8. ">Jobe 1993</a>; <a href="./references#CD000144-bbs2-0061" title="WarrenJB , AndersonJM . Core Concepts: Respiratory Distress Syndrome. NeoReviews2009;10(7):351‐61. ">Warren 2009</a>). The incidence of RDS increases with decreasing gestational age. Sixty per cent of infants born at less than 28 weeks gestation will have RDS, 30% of infants born between 28 and 34 weeks gestation will develop RDS, and less than 5% of infants born after 34 weeks will develop RDS (<a href="./references#CD000144-bbs2-0061" title="WarrenJB , AndersonJM . Core Concepts: Respiratory Distress Syndrome. NeoReviews2009;10(7):351‐61. ">Warren 2009</a>). </p> <p>The pathophysiology of RDS is secondary to lung immaturity and surfactant deficiency. Most infants with RDS are born prior to the alveolarization stage of lung development (which occurs at ˜ 32 weeks gestation) (<a href="./references#CD000144-bbs2-0041" title="JobeA . Why surfactant works for respiratory distress syndrome?. NeoReviews2006;7:e95‐106. ">Jobe 2006</a>). At lower gestational ages, pulmonary surfactant is not produced in sufficient amounts or with the correct composition of phospholipids and surfactant proteins due to the immaturity of the type II pneumocyte where surfactant is produced, stored and secreted (<a href="./references#CD000144-bbs2-0063" title="WrightJR , ClementsJA . Metabolism and turnover of lung surfactant. American Review of Respiratory Disease1987;136(2):426‐44. ">Wright 1997</a>; <a href="./references#CD000144-bbs2-0061" title="WarrenJB , AndersonJM . Core Concepts: Respiratory Distress Syndrome. NeoReviews2009;10(7):351‐61. ">Warren 2009</a>). These cells start to differentiate during the canalicular phase of lung development and reach their final, mature stage by the alveolar phase (˜ 32 weeks gestation) (<a href="./references#CD000144-bbs2-0041" title="JobeA . Why surfactant works for respiratory distress syndrome?. NeoReviews2006;7:e95‐106. ">Jobe 2006</a>).  </p> <p>Surfactant is composed of phospholipids and four surfactant proteins, A, B, C and D (SP A, B, C, D). Endogenous surfactant is packaged in the lamellar bodies of the type II pneumocyte, which secrete the surfactant by exocytosis into the extracellular space. Phosphotidylcholine is the major phospholipid found in surfactant and is responsible for decreasing the surface tension at the air‐water interface in the alveoli (<a href="./references#CD000144-bbs2-0032" title="ClementsJA . Functions of the alveolar lining. American Review of Respiratory Disease1977;115(6 Pt 2):67‐71. ">Clements 1977</a>; <a href="./references#CD000144-bbs2-0041" title="JobeA . Why surfactant works for respiratory distress syndrome?. NeoReviews2006;7:e95‐106. ">Jobe 2006</a>). The surfactant proteins all have different functions (<a href="./references#CD000144-bbs2-0048" title="PossmayerF . The role of surfactant‐associated proteins. American Review of Respiratory Disease1990;142(4):749‐52. ">Possmayer 1990</a>). SP B and C facilitate the adsorption of the surfactant lipids to the air‐water interface and are essential for the surfactant’s surface tension lowering properties (<a href="./references#CD000144-bbs2-0034" title="GowerWA , WertSE , NogeeLM . Inherited surfactant disorders. NeoReviews2008;9(10):458‐67. ">Gower 2008</a>). SP A and D are involved in innate immunity and immunomodulation (<a href="./references#CD000144-bbs2-0034" title="GowerWA , WertSE , NogeeLM . Inherited surfactant disorders. NeoReviews2008;9(10):458‐67. ">Gower 2008</a>). Genetic SP B deficiency is a cause of fatal neonatal respiratory disease (<a href="./references#CD000144-bbs2-0042" title="NogeeLM , deMelloDE , DehnerLP , ColtenHR . Brief Report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. New England Journal of Medicine1993;328(6):406‐10. ">Nogee 1993</a>; <a href="./references#CD000144-bbs2-0062" title="WhitsettJA , NogeeLM , WeaverTE , HorowitzAD . Human surfactant protein B: structure, function, regulation, and genetic disease. Physiological Reviews1995;75(4):749‐57. ">Whitsett 1995</a>; <a href="./references#CD000144-bbs2-0034" title="GowerWA , WertSE , NogeeLM . Inherited surfactant disorders. NeoReviews2008;9(10):458‐67. ">Gower 2008</a>). SP C deficiency is associated with respiratory disease that occurs later in life, but the presentation is variable with some patients presenting in the neonatal period with a rapid deterioration in respiratory status or patients present with interstitial lung disease later in life (<a href="./references#CD000144-bbs2-0043" title="NogeeLM . Alterations in SP‐B and SP‐C expression in neonatal lung disease. Annual Review of Physiology2004;66:601‐23. ">Nogee 2004</a>; <a href="./references#CD000144-bbs2-0034" title="GowerWA , WertSE , NogeeLM . Inherited surfactant disorders. NeoReviews2008;9(10):458‐67. ">Gower 2008</a>).  </p> <p>The result of preterm birth is decreased surface area for gas exchange and increased surface tension at the alveolar level resulting in atelectasis and intra‐pulmonary shunting leading to ventilation‐perfusion mismatch and hypoxia with subsequent respiratory failure (<a href="./references#CD000144-bbs2-0061" title="WarrenJB , AndersonJM . Core Concepts: Respiratory Distress Syndrome. NeoReviews2009;10(7):351‐61. ">Warren 2009</a>). Progressive atelectasis, which results in decreased functional residual capacity, causes further lung injury that leads to exudation of protein into the extracellular space, edema and further inactivation of endogenous pulmonary surfactant (<a href="./references#CD000144-bbs2-0040" title="JobeAH . Pulmonary surfactant therapy. New England Journal of Medicine1993;328(12):861‐8. ">Jobe 1993</a>; <a href="./references#CD000144-bbs2-0061" title="WarrenJB , AndersonJM . Core Concepts: Respiratory Distress Syndrome. NeoReviews2009;10(7):351‐61. ">Warren 2009</a>). </p> <p>Clinically, RDS is characterized by increased work of breathing and cyanosis (<a href="./references#CD000144-bbs2-0061" title="WarrenJB , AndersonJM . Core Concepts: Respiratory Distress Syndrome. NeoReviews2009;10(7):351‐61. ">Warren 2009</a>). Chest radiographs reveal the characteristic 'ground glass' appearance to the lung secondary to atelectasis with superimposed air bronchograms. Without intervention, RDS is progressive and potentially fatal. </p> </section> <section id="CD000144-sec-0031"> <h3 class="title" id="CD000144-sec-0031">Description of the intervention</h3> <p>Pulmonary surfactant decreases alveolar surface tension and prevents alveolar collapse and atelectasis, allowing for increased functional residual capacity, increased compliance, and improved oxygenation and ventilation (<a href="./references#CD000144-bbs2-0040" title="JobeAH . Pulmonary surfactant therapy. New England Journal of Medicine1993;328(12):861‐8. ">Jobe 1993</a>; <a href="./references#CD000144-bbs2-0061" title="WarrenJB , AndersonJM . Core Concepts: Respiratory Distress Syndrome. NeoReviews2009;10(7):351‐61. ">Warren 2009</a>). In infants that are deficient in surfactant or have surfactant inactivation, surfactant replacement therapy has been shown to improve oxygenation and chest X‐ray (CXR) findings within one hour after administration (<a href="./references#CD000144-bbs2-0061" title="WarrenJB , AndersonJM . Core Concepts: Respiratory Distress Syndrome. NeoReviews2009;10(7):351‐61. ">Warren 2009</a>).  </p> </section> <section id="CD000144-sec-0032"> <h3 class="title" id="CD000144-sec-0032">How the intervention might work</h3> <p>Randomized controlled trials have demonstrated the effectiveness of surfactant therapy in both the prevention and treatment of RDS in infants that are at risk of or with the disease. Surfactant administration decreases the severity of respiratory distress, decreases the frequency of pneumothorax, increases survival without chronic lung disease, and decreases mortality (<a href="./references#CD000144-bbs2-0053" title="SollRF , McQueenMC . Respiratory distress syndrome. In: SinclairJC , BrackenMB editor(s). Effective Care of the Newborn Infant. Oxford: Oxford University Press, 1992:325‐58. ">Soll 1992</a>). Surfactant preparations are now widely used and have been credited with recent improvements in overall infant mortality (<a href="./references#CD000144-bbs2-0038" title="HorbarJD , WrightEC , OnstadL . Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601‐1300 grams at birth. The Members of the National Institute of Child Health and Human Development Neonatal Research Network. Pediatrics1993;92(2):191‐6. ">Horbar 1993b</a>, <a href="./references#CD000144-bbs2-0051" title="SchwartzRM , LubyAM , ScanlonJW , KelloggRJ . Effect of surfactant on morbidity, mortality and resource use in newborns weighing 500 to 1500 g. New England Journal of Medicine1994;330(21):1476‐80. ">Schwartz 1994</a>). A wide variety of surfactant preparations have been developed and tested. These include synthetic surfactants and surfactants derived from animal sources. Synthetic surfactants can be protein free or contain peptides that are thought to mimic proteins found in pulmonary surfactant (see below) (<a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a>; <a href="./references#CD000144-bbs2-0045" title="PfisterRH , SollRF . New synthetic surfactants: the next generation?. Biology of the Neonate2005;87(4):338‐44. ">Pfister 2005</a>). Animal derived surfactants are derived from both bovine and porcine sources, and all contain varying degrees of SP B and C as well as phospholipids (<a href="./references#CD000144-bbs2-0061" title="WarrenJB , AndersonJM . Core Concepts: Respiratory Distress Syndrome. NeoReviews2009;10(7):351‐61. ">Warren 2009</a>). Although clinical trials have demonstrated that both synthetic surfactants and animal derived surfactant preparations are effective, comparison in animal models has suggested that there may be greater efficacy of animal derived surfactant products, perhaps due to the protein content of these surfactant preparations (<a href="./references#CD000144-bbs2-0060" title="TooleyWH , ClementsJA , MuramatsuK , BrownCL , SchlueterMA . Lung function in prematurely delivered rabbits treated with a synthetic surfactant. American Review of Respiratory Disease1987;136(3):651‐6. ">Tooley 1987</a>). </p> <p>Timing of surfactant administration also plays an important role in the therapeutic benefit of surfactant replacement therapy (SRT). Although aggressive prophylactic treatment may no longer be necessary (<a href="./references#CD000144-bbs2-0050" title="Rojas‐ReyesMX , MorleyCJ , SollR . Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD000510.pub2] ">Rojas‐Reyes 2012</a>), studies have demonstrated that early SRT vs. late, selective SRT improves outcomes with significant reductions in the rates of pneumothorax, pulmonary interstitial emphysema (PIE), mortality, bronchopulmonary dysplasia (BPD) or death (<a href="./references#CD000144-bbs2-0030" title="BahadueFL , SollR . Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD001456.pub2] ">Bahadue 2012</a>).  </p> </section> <section id="CD000144-sec-0033"> <h3 class="title" id="CD000144-sec-0033">Why it is important to do this review</h3> <p>Multiple systematic reviews have addressed the use of animal derived surfactant preparations or synthetic surfactant preparations in the prevention or treatment of RDS. Meta‐analyses of the original randomized controlled trials of surfactant for the treatment and prevention of RDS were first published in <i>Effective Care of the Newborn</i> (<a href="./references#CD000144-bbs2-0053" title="SollRF , McQueenMC . Respiratory distress syndrome. In: SinclairJC , BrackenMB editor(s). Effective Care of the Newborn Infant. Oxford: Oxford University Press, 1992:325‐58. ">Soll 1992</a>). Since then, multiple systematic reviews have been published in <i>The Cochrane Library</i> including reviews of protein free synthetic surfactant for the prevention and treatment of RDS (<a href="./references#CD000144-bbs2-0054" title="SollRF . Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD001149] ">Soll 2000a</a>; <a href="./references#CD000144-bbs2-0057" title="SollR , OzekE . Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD001079.pub2] ">Soll 2010</a>) and reviews of animal derived surfactant for the prevention and treatment of RDS (<a href="./references#CD000144-bbs2-0055" title="SollRF , OzekE . Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews2000, Issue 2. [DOI: 10.1002/14651858.CD000511] ">Soll 2000b</a>; <a href="./references#CD000144-bbs2-0052" title="SegerN , SollR . Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007836] ">Seger 2009</a>). </p> <p>Systematic reviews that compare different treatment strategies have been published (<a href="./references#CD000144-bbs2-0058" title="StevensTP , HarringtonEW , BlennowM , SollRF . Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003063.pub3] ">Stevens 2007</a>; <a href="./references#CD000144-bbs2-0056" title="SollR , OzekE . Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD000141.pub2] ">Soll 2009</a>; <a href="./references#CD000144-bbs2-0030" title="BahadueFL , SollR . Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD001456.pub2] ">Bahadue 2012</a>; <a href="./references#CD000144-bbs2-0050" title="Rojas‐ReyesMX , MorleyCJ , SollR . Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews2012, Issue 3. [DOI: 10.1002/14651858.CD000510.pub2] ">Rojas‐Reyes 2012</a>). </p> <p>Other reviews have addressed the method of instillation of surfactant (<a href="./references#CD000144-bbs2-0026" title="Abdel‐LatifME , OsbornDA . Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD008309.pub2] ">Abdel‐Latif 2011a</a>; <a href="./references#CD000144-bbs2-0027" title="Abdel‐LatifME , OsbornDA . Pharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk of respiratory distress syndrome. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD008311.pub2] ">Abdel‐Latif 2011b</a>; <a href="./references#CD000144-bbs2-0028" title="Abdel‐LatifME , OsbornDA . Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD008310.pub2] ">Abdel‐Latif 2012</a>) as well as the use of surfactant replacement therapy in conditions other than RDS (<a href="./references#CD000144-bbs2-0033" title="ElShahedAI , DargavilleP , OhlssonA , SollRF . Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002054.pub2] ">El Shahed 2007</a>; <a href="./references#CD000144-bbs2-0029" title="AzizA , OhlssonA . Surfactant for pulmonary haemorrhage in neonates. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD005254.pub3] ">Aziz 2012</a>; <a href="./references#CD000144-bbs2-0059" title="TanK , LaiNM , SharmaA . Surfactant for bacterial pneumonia in late preterm and term infants. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD008155.pub2] ">Tan 2012</a>; <a href="./references#CD000144-bbs2-0036" title="HahnS , ChoiHJ , SollR , DargavillePA . Lung lavage for meconium aspiration syndrome in newborn infants. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD003486.pub2] ">Hahn 2013</a>). </p> <p>This review updates the previous reviews of animal derived surfactant extract vs. synthetic surfactant in the prevention and treatment of established RDS published in <i>The Cochrane Library</i> (<a href="./references#CD000144-bbs2-0064" title="SollRF . Natural surfactant extract vs synthetic surfactant in the treatment of established respiratory distress syndrome. Cochrane Database of Systematic Reviews1997, Issue 3. [DOI: 10.1002/14651858.CD000144] ">Soll 1997</a>; <a href="./references#CD000144-bbs2-0065" title="SollRF , BlancoF . Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews2001, Issue 2. [DOI: 10.1002/14651858.CD000144] ">Soll 2001</a>). Clinical trials that compare animal derived surfactant extract to protein free synthetic surfactant in the treatment or prevention of respiratory distress syndrome have been included in this systematic review. Trials that compare animal derived surfactant extract to protein containing synthetic surfactant and trials that compare protein free synthetic surfactant to protein containing synthetic surfactant are addressed by other reviews (<a href="./references#CD000144-bbs2-0046" title="PfisterRH , SollRF , WiswellT . Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD006069.pub3] ">Pfister 2007</a>; <a href="./references#CD000144-bbs2-0047" title="PfisterRH , SollR , WiswellTE . Protein‐containing synthetic surfactant versus protein‐free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006180.pub2] ">Pfister 2009</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000144-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000144-sec-0034"></div> <p>To compare the effect of protein free synthetic surfactant to animal derived surfactant extracts surfactant in preterm infants at risk for or having respiratory distress syndrome (RDS). </p> <p>Separate analyses were done for trials of prophylaxis and trials of selective treatment (rescue). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000144-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000144-sec-0035"></div> <section id="CD000144-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000144-sec-0037"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials and quasi‐randomized controlled trials were considered for this review. </p> </section> <section id="CD000144-sec-0038"> <h4 class="title">Types of participants</h4> <p>Preterm infants (less than 37 weeks gestation) at risk for or having RDS.</p> </section> <section id="CD000144-sec-0039"> <h4 class="title">Types of interventions</h4> <p>Studies in which preterm infants were randomly allocated to receive an animal derived surfactant extract compared to a protein free synthetic surfactant, using either a prophylactic or selective treatment strategy. </p> </section> <section id="CD000144-sec-0040"> <h4 class="title">Types of outcome measures</h4> <section id="CD000144-sec-0041"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD000144-list-0001"> <li> <p>Mortality</p> </li> <li> <p>Bronchopulmonary dysplasia (BPD) (defined as oxygen dependency at 28 to 30 days of age) </p> </li> <li> <p>Chronic lung disease (CLD) (defined as oxygen dependency at 36 weeks postmenstrual age) </p> </li> <li> <p>BPD or death</p> </li> <li> <p>CLD or death</p> </li> </ul> </p> </section> <section id="CD000144-sec-0042"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD000144-list-0002"> <li> <p>Pneumothorax</p> </li> <li> <p>Patent ductus arteriosus (PDA) (either clinical diagnosis or need for treatment)</p> </li> <li> <p>Bacterial sepsis</p> </li> <li> <p>Necrotizing enterocolitis (NEC) (Bell's stage II or greater) (<a href="./references#CD000144-bbs2-0031" title="BellMJ , TernbergJL , FeiginRD , KeatingJP , MarshallR , BartonL , et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery1978;187(1):1‐7. ">Bell 1978</a>) </p> </li> <li> <p>Intraventricular hemorrhage (IVH) [all intraventricular hemorrhage and severe intraventricular hemorrhage (Grades 3 and 4)] (<a href="./references#CD000144-bbs2-0044" title="PapileLA , BursteinJ , BursteinR , KofflerH . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics1978;92(4):529‐34. ">Papile 1978</a>) </p> </li> <li> <p>Retinopathy of prematurity (ROP) [any stage, severe (stages 3 and 4)](<a href="./references#CD000144-bbs2-0039" title="International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Archives of Ophthalmology2005;123(7):991‐9. ">ICCROP 2005</a>) </p> </li> </ul> </p> </section> </section> </section> <section id="CD000144-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <p>We used the standard search methods of the Cochrane Neonatal Review Group.</p> <section id="CD000144-sec-0044"> <h4 class="title">Electronic searches</h4> <p>We updated searches of the Cochrane Central Register of Controlled Trials (CENTRAL) in <i>The Cochrane Library</i> (2014), PubMed, CINAHL and EMBASE (1975 through November 2014). We did not include any language restrictions. The search terms were: pulmonary surfactant; limits; age groups, infants; publication type, clinical trial. </p> </section> <section id="CD000144-sec-0045"> <h4 class="title">Searching other resources</h4> <p>We searched previous reviews and cross references, abstracts, conference and symposia proceedings, approached expert informants, and undertook journal handsearching in the English language. The abstracts of the Society for Pediatric Research (USA) (published in Pediatric Research) for the years 1985 to 2010 were searched by hand using the following key words: {surfactant} AND {respiratory distress syndrome}. For abstract books that did not include keywords, the search was limited to relevant sections such as pulmonology and neonatology. </p> <p>We searched for any on‐going or recently completed and unpublished trials using clinicaltrials.gov, controlled‐trials.com, and who.int/ictrp. </p> </section> </section> <section id="CD000144-sec-0046"> <h3 class="title" id="CD000144-sec-0046">Data collection and analysis</h3> <p>We used the methods of the Cochrane Neonatal Review Group for data collection and analysis. </p> <section id="CD000144-sec-0047"> <h4 class="title">Selection of studies</h4> <p>We included all randomized and quasi‐randomized controlled trials that fulfilled the selection criteria described in the previous section. RS and SA independently reviewed the results of the updated search and selected studies for inclusion. We resolved any disagreement by discussion. </p> </section> <section id="CD000144-sec-0048"> <h4 class="title">Data extraction and management</h4> <p>We used a data extraction form specifically designed for the study. Two review authors (SA, RS) separately extracted, assessed and coded all data for each additional included study.  </p> <p>We collected information on clinical outcomes, including the incidence of pneumothorax, PDA, IVH (any IVH and severe IVH, grades 3 or 4), BPD, CLD, ROP, and mortality. We resolved differences in assessment by discussion. </p> <p>For each study, final data were entered into RevMan by one review author (RS) and then checked for accuracy by a second review author (SA). We resolved discrepancies through discussion or by involving RP as a third assessor.  </p> <p>We attempted to contact authors of the original reports to provide further details when information regarding any of the above was unclear. </p> </section> <section id="CD000144-sec-0049"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the standard method of the Cochrane Neonatal Review Group. RS and SA independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000144-bbs2-0037" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved any disagreement by discussion or by involving RP as a third assessor.  </p> <p>The methodological quality of the studies was assessed using the following criteria.</p> <p> <ol id="CD000144-list-0003"> <li> <p>Sequence generation (checking for possible selection bias). For each included study, we categorized the method used to generate the allocation sequence as: </p> <ol id="CD000144-list-0004"> <li> <p>low risk (any truly random process e.g. random number table; computer random number generator); </p> </li> <li> <p>high risk (any non‐random process e.g. odd or even date of birth; hospital or clinic record number); </p> </li> <li> <p>unclear risk. </p> </li> </ol> </li> <li> <p>Allocation concealment (checking for possible selection bias). For each included study, we categorized the method used to conceal the allocation sequence as:  </p> <ol id="CD000144-list-0005"> <li> <p>low risk (e.g. telephone or central randomization; consecutively numbered sealed opaque envelopes); </p> </li> <li> <p>high risk (open random allocation; unsealed or non‐opaque envelopes, alternation; date of birth); </p> </li> <li> <p>unclear risk.</p> </li> </ol> </li> <li> <p>Blinding (checking for possible performance bias). For each included study, we categorized the methods used to blind study participants and personnel from knowledge of which intervention a participant received. Blinding was assessed separately for different outcomes or classes of outcomes. We categorized the methods as: </p> <ol id="CD000144-list-0006"> <li> <p>low risk, high risk or unclear risk for participants;</p> </li> <li> <p>low risk, high risk or unclear risk for personnel;</p> </li> <li> <p>low risk, high risk or unclear risk for outcome assessors. </p> </li> </ol> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). For each included study and for each outcome, we described the completeness of data including attrition and exclusions from the analysis. We noted whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total number of randomized participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported or supplied by the trial authors, we re‐included missing data in the analyses. We categorized the methods as: </p> <ol id="CD000144-list-0007"> <li> <p>low risk (&lt; 20% missing data);</p> </li> <li> <p>high risk (≥ 20% missing data);</p> </li> <li> <p>unclear risk.</p> </li> </ol> </li> <li> <p>Selective reporting bias. For each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. We assessed the methods as: </p> <ol id="CD000144-list-0008"> <li> <p>low risk (where it is clear that all of the study’s pre‐specified outcomes and all expected outcomes of interest to the review have been reported);  </p> </li> <li> <p>high risk (where not all the study’s pre‐specified outcomes have been reported; one or more reported primary outcomes were not pre‐specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported); </p> </li> <li> <p>unclear risk.</p> </li> </ol> </li> <li> <p>Other sources of bias. For each included study, we described any important concerns we had about other possible sources of bias (e.g. whether there was a potential source of bias related to the specific study design or whether the trial was stopped early due to some data‐dependent process). We assessed whether each study was free of other problems that could put it at risk of bias as: </p> <ol id="CD000144-list-0009"> <li> <p>low risk; high risk; unclear risk.  </p> </li> </ol> </li> <li> <p>Overall risk of bias (described in Table 8.5c in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>).  </p> </li> </ol> </p> <p>We made explicit judgements regarding whether studies were at high risk of bias, according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000144-bbs2-0037" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it likely to impact on the findings. If needed, we planned to explore the impact of the level of bias through undertaking sensitivity analyses (see 'Sensitivity analysis' below). </p> </section> <section id="CD000144-sec-0050"> <h4 class="title">Measures of treatment effect</h4> <p>We used the standard methods of the Neonatal Review Group to analyze the data.</p> <p>We performed statistical analyses using the Review Manager software (<a href="./references#CD000144-bbs2-0049" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>). Dicotomous data were analyzed using relative risk (RR), risk difference (RD) and the number needed to treat to benefit (NNTB) or number needed to treat to harm (NNTH). The 95% confidence interval (CI) was reported on all estimates. </p> <p>No continuous outcomes were included in this review. If included, we planned to analyze continuous data using weighted mean difference (WMD), or the standardized mean difference (SMD) to combine trials that measured the same outcome but used different methods. </p> </section> <section id="CD000144-sec-0051"> <h4 class="title">Unit of analysis issues</h4> <p>For clinical outcomes such as episodes of sepsis, we analyzed the data as proportion of neonates having one or more episodes. </p> </section> <section id="CD000144-sec-0052"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, levels of attrition were noted. The impact of including studies with high levels of missing data in the overall assessment of treatment effect was explored by using sensitivity analysis. </p> <p>All outcomes analyses were on an intention to treat basis that is we included all participants randomized to each group in the analyses. The denominator for each outcome in each trial was the number randomized minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD000144-sec-0053"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined heterogeneity between trials by inspecting the forest plots and quantifying the impact of heterogeneity using the I<sup>2</sup> statistic. If noted, we planned to explore the possible causes of statistical heterogeneity using pre‐specified subgroup analysis (for example differences in study quality, participants, intervention regimens, or outcome assessments). </p> </section> <section id="CD000144-sec-0054"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed possible publication bias and other biases using the symmetry or asymmetry of funnel plots. </p> <p>For included trials that were recently performed (and therefore prospectively registered) we explored possible selective reporting of study outcomes by comparing the primary and secondary outcomes in the reports with the primary and secondary outcomes proposed at trial registration, using the websites www.clinicaltrials.gov and www.controlled‐trials.com. If such discrepancies were found, we planned to contact the primary investigators to obtain missing outcome data on outcomes pre‐specified at trial registration. </p> </section> <section id="CD000144-sec-0055"> <h4 class="title">Data synthesis</h4> <p>Where meta‐analysis was judged to be appropriate, the analysis was done using the Review Manager software (<a href="./references#CD000144-bbs2-0049" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>), supplied by The Cochrane Collaboration. We used the Mantel‐Haenszel method for estimates of typical RR and RD. No continuous outcomes were included in this review. We planned to analyze continuous measures using the inverse variance method, if included. </p> <p>We used the fixed‐effect model for all meta‐analyses.</p> </section> <section id="CD000144-sec-0056"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did separate analyses for trials of prophylaxis and trials of selective treatment (rescue). </p> </section> <section id="CD000144-sec-0057"> <h4 class="title">Sensitivity analysis</h4> <p>We planned sensitivity analyses for situations that might affect the interpretation of significant results (for example where there was risk of bias associated with the quality of some of the included trials or missing outcome data). None were thought necessary in this review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000144-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000144-sec-0058"></div> <section id="CD000144-sec-0059"> <h3 class="title">Description of studies</h3> <p>The review included the following 15 studies.<br/> Prevention trials: <a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a>; <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a>.<br/> Selective treatment trials: <a href="./references#CD000144-bbs2-0002" title="AlvaradoM , HingreR , HakasonD , GrossS . Clinical trial of survanta versus exosurf in infants &lt; 1500g with respiratory distress syndrome. Pediatric Research1993;33:314A. ">Alvarado 1993</a>; <a href="./references#CD000144-bbs2-0005" title="HorbarJD , WrightLL , SollRF , WrightEC , FanaroffAA , KoronesSB , et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. Journal of Pediatrics1993;123(5):757‐66. ">Horbar 1993</a>; <a href="./references#CD000144-bbs2-0013" title="PearlmanSA , LeefKH , StefanoJL , et al. A randomized trial comparing Exosurf versus Survanta in the treatment of neonatal RDS. Pediatric Research1993;33:340A. ">Pearlman 1993</a>; <a href="./references#CD000144-bbs2-0014" title="SehgalSS , EwingCK , RichardsT , TaeuschHW . Modified bovine surfactant (Survanta) versus a protein free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. Journal of the National Medical Association1994;86(1):46‐52. ">Sehgal 1994</a>; <a href="./references#CD000144-bbs2-0006" title="HudakML , FarrellEE , RosenbergAA , JungAL , AutenRL , DurandDJ , et al. A multicenter randomized masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. Journal of Pediatrics1996;128(3):396‐406. ">Hudak 1996</a>; <a href="./references#CD000144-bbs2-0015" title="The Vermont Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics1996;97(1):1‐6. ">VT Oxford 1996</a>; <a href="./references#CD000144-bbs2-0010" title="ModanlouHD , BeharryK , PadillaG , NorrisK , SafvatiS , ArandaJV . Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. Journal of Perinatology1997;17(6):455‐60. ">Modanlou 1997</a>; <a href="./references#CD000144-bbs2-0012" title="MurdochE , KempleyST . Randomized trial examining cerebral haemodynamics following artificial or animal surfactant. Acta Paediatrica1998;87(4):411‐5. MurdochE , KempleyST . The effects of synthetic and natural surfactant on fluid balance in acute respiratory distress syndrome. European Journal of Pediatrics2000;159(10):767‐9 . ">Murdoch 1998</a>; <a href="./references#CD000144-bbs2-0003" title="daCostaDE , PaiMG , Al KhusaibySM . Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country. Pediatric Pulmonology1999;27(5):312‐7. ">daCosta 1999</a>; <a href="./references#CD000144-bbs2-0004" title="HalahakoonWL . A study of cerebral function following surfactant treatment for respiratory distress syndrome (Doctoral dissertation). Queen's University of Belfast (UK)1999. ">Halahakoon 1999</a>; <a href="./references#CD000144-bbs2-0009" title="LloydJ , ToddDA , JohnE . Serial phospholipid analysis in preterm infants: comparison of Exosurf and Survanta. Early Human Development1999;54(2):157‐68. ">Lloyd 1999</a>; <a href="./references#CD000144-bbs2-0001" title="AinsworthSB , BeresfordMW , MilliganDW , ShawNJ , MatthewsJN , FentonAC , et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25‐29 weeks' gestation: a randomised trial. Lancet2000;355(9213):1387‐92. ">Ainsworth 2000</a>; <a href="./references#CD000144-bbs2-0008" title="KukkonenAK , VirtanenM , JarvenpaaAL , PokelaML , IkonenS , FellmanV . Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?. Acta Paediatrica2000;89(5):556‐61. ">Kukkonen 2000</a>. </p> <section id="CD000144-sec-0060"> <h4 class="title">Prevention trials</h4> <p><a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a>: conducted a multicenter randomized controlled trial to compare the efficacy and safety of a synthetic surfactant colfosceril palmitate (Exosurf Neonatal, Burroughs Wellcome) and a surfactant extract of calf lung lavage (Infasurf, Forest Laboratories) in the prevention of neonatal respiratory distress syndrome. Premature infants less than 29 weeks gestational age were randomly assigned to prophylactic surfactant administration with colfosceril palmitate (n = 438) or Infasurf (n = 433) at birth and, if still intubated, at 12 and 24 hours of age. Crossover treatment was allowed within 72 hours of age if severe respiratory failure persisted after three doses of the assigned surfactant. The clinicians were unaware of treatment assignment. Primary outcome measures included the incidence of RDS, the incidence of death due to RDS, and the incidence of survival without BPD at 28 days after birth. Of 871 randomized infants, 18 infants did not receive treatment with a study surfactant, and 25 infants did not meet all eligibility criteria. The primary analysis of efficacy was performed in the 846 eligible infants and analysis of safety outcomes in the 853 infants who received study surfactant. Demographic characteristics did not differ between the two treatment groups. Compared with colfosceril palmitate, calf lung surfactant treatment resulted in a decrease in the incidence of RDS (16% vs. 42%) and a decrease in death due to RDS (1.7% vs. 5.4%) but did not increase the incidence of survival without BPD at 28 days. Treatment with calf lung surfactant resulted in significant improvement in several secondary outcome measures including lower average FIO<sub>2</sub> and lower average mean airway pressure for the first 72 hours of life. Crossover surfactant treatment was significantly less frequent in the animal derived surfactant compared with the colfosceril palmitate group (1% vs. 6%). Animal surfactant‐treated infants had significantly less air leak (8% vs. 14%). Intraventricular hemorrhage (IVH) occurred more frequently in animal surfactant‐treated infants (39.0% vs. 29.9%) but the incidence of severe IVH (Grade 3 and 4) did not differ between the two groups (animal derived 11.8% vs. synthetic 8.3%). </p> <p><a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a>: Moya and coworkers compared the efficacy of lucinactant (Discovery Laboratories, Doylestown, PA), a synthetic surfactant containing a functional SP B mimic, with colfosceril palmitate (GlaxoSmithKline, Brentford, United Kingdom), a non‐protein containing synthetic surfactant, and beractant (Abbott Laboratories, Abbott Park, IL), a bovine derived surfactant, in the prevention of RDS. A total of 1294 very preterm infants weighing 600 to 1250 g and ≤ 32 weeks gestational age were randomly assigned to receive colfosceril palmitate (n = 509), lucinactant (n = 527), or beractant (n = 258) within 20 to 30 minutes after birth. Only the comparison groups receiving colfosceril palmitate and beractant were included in this review. Primary outcome measures were the rates of RDS at 24 hours and the rates of death related to RDS during the first 14 days after birth. All‐cause mortality rates, BPD rates, and rates of other complications of prematurity were pre‐specified secondary outcomes. The primary outcomes, air leaks, and causes of death were assigned, with pre‐specified definitions, by an independent, masked adjudication committee. </p> </section> <section id="CD000144-sec-0061"> <h4 class="title">Selective treatment trials</h4> <p><a href="./references#CD000144-bbs2-0002" title="AlvaradoM , HingreR , HakasonD , GrossS . Clinical trial of survanta versus exosurf in infants &lt; 1500g with respiratory distress syndrome. Pediatric Research1993;33:314A. ">Alvarado 1993</a> (abstract): conducted a randomized controlled trial of the modified bovine surfactant extract beractant (Survanta, Ross Laboratories) with synthetic surfactant colfosceril palmitate (Exosurf Neonatal, Burroughs Wellcome) in the treatment of very low birth weight infants with RDS. Sixty‐six infants with birth weights less than or equal to 1500 g who required assisted ventilation, supplemental oxygen greater than 40%, and had radiographic evidence of RDS were entered in the study. Infants received beractant (n = 33) or colfosceril palmitate (n = 33) by random assignment within 24 hours of birth, and received additional doses at 12 hour intervals (up to four doses) if the infants remained on assisted ventilation and required supplemental oxygen greater than 30%. Infants who received beractant and colfosceril palmitate were similar regarding birth weight (1000 ± 280 g and 990 ± 237 g respectively) and gestational age (27 ± 3 weeks and 27 ± 2 weeks), baseline clinical characteristics and ventilator settings. Mean time from birth to treatment was comparable between the two groups (beractant 5 ± 3 hours, colfosceril palmitate 4 ± 2 hours). The authors reported a significant improvement in the duration of mechanical ventilation, supplemental oxygen and hospital stay associated with beractant treatment. </p> <p><a href="./references#CD000144-bbs2-0005" title="HorbarJD , WrightLL , SollRF , WrightEC , FanaroffAA , KoronesSB , et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. Journal of Pediatrics1993;123(5):757‐66. ">Horbar 1993</a>: conducted a multicenter randomized controlled trial to compare the efficacy of synthetic surfactant colfosceril palmitate (Exosurf Neonatal, Burroughs Wellcome) and modified bovine surfactant extract beractant (Survanta, Ross Laboratories) for the treatment of neonatal RDS. The study was conducted at 11 tertiary care university neonatal intensive care units participating in the National Institute of Child Health and Human Development Neonatal Research Network. Newborn infants (n = 617) weighing 501 to 1500 g with RDS who were receiving assisted ventilation with 30% oxygen or more within six hours of birth were enrolled. Infants were randomly assigned to receive up to four intratracheal doses of either colfosceril palmitate (n = 309) or beractant (n = 308). During the 72 hours after the first surfactant dose, the average fraction of inspired oxygen (FiO<sub>2</sub>) (± SEM) was 0.50 ± 0.01 for colfosceril palmitate and 0.42 ± 0.01 for beractant (difference 0.08, 95% CI 0.05 to 0.11); the average MAP (± SEM) was 7.64 ± 0.21 cm H<sub>2</sub>O for colfosceril palmitate and 6.93 ± 0.21 cm H<sub>2</sub>O for beractant (difference 0.71 cm H<sub>2</sub>O, 95% CI 0.13 to 1.29 cm H<sub>2</sub>O). There was no difference between the groups in the incidence of other neonatal morbidities or in the duration of hospitalization, assisted ventilation, or supplemental oxygen administration. </p> <p><a href="./references#CD000144-bbs2-0013" title="PearlmanSA , LeefKH , StefanoJL , et al. A randomized trial comparing Exosurf versus Survanta in the treatment of neonatal RDS. Pediatric Research1993;33:340A. ">Pearlman 1993</a> (abstract): conducted a quasi‐randomized controlled trial of synthetic surfactant colfosceril palmitate (Exosurf Neonatal, Burroughs Wellcome) compared with modified bovine surfactant extract beractant (Survanta, Ross Laboratories) in the treatment of RDS. One hundred and twenty‐one premature infants with evidence of RDS were entered in the study. Infants received beractant (n = 57) or colfosceril palmitate (n = 64) on alternate months. Subsequent doses were given at the discretion of the attending physician. Infants who received beractant and colfosceril palmitate were similar regarding birth weight (1322 ± 751 g and 1229 ± 622 g respectively), gestational age (28.4 ± 4.2 weeks and 28.7 ± 3.6 weeks), and baseline Apgar scores. Each group received an equal number of doses (beractant 1.8 ± 1.0, colfosceril palmitate 2.0 ± 1.0). The authors reported no statistically significant differences in the duration of mechanical ventilation, clinical complications, or mortality. </p> <p><a href="./references#CD000144-bbs2-0014" title="SehgalSS , EwingCK , RichardsT , TaeuschHW . Modified bovine surfactant (Survanta) versus a protein free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. Journal of the National Medical Association1994;86(1):46‐52. ">Sehgal 1994</a>: conducted a prospective, randomized, non‐blinded study to determine whether infants with RDS who were treated with modified bovine surfactant extract beractant (Survanta, Ross Laboratories) had earlier and larger responses in gas exchange when compared with similar infants treated with a synthetic surfactant colfosceril palmitate (Exosurf Neonatal, Burroughs Wellcome). Forty‐one infants weighing between 600 g and 1750 g at birth with RDS of sufficient severity to require assisted ventilation with an FiO<sub>2</sub> &gt; 0.39 were enrolled in the study and treated with surfactant from one to eight hours after birth. Infants were randomly selected to receive treatment with either colfosceril palmitate or beractant. Despite randomization, the beractant group was over represented with factors associated with greater severity of RDS (lower birth weight, more males, and fewer African Americans). No statistically significant difference was found in the primary outcome measure (arterial‐alveolar (a/A) PaO<sub>2</sub> &gt; 0.3 at 24 hours). </p> <p><a href="./references#CD000144-bbs2-0015" title="The Vermont Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics1996;97(1):1‐6. ">VT Oxford 1996</a>, Vermont‐Oxford Neonatal Network: conducted a multicenter randomized controlled trial to compare the efficacy of synthetic surfactant colfosceril palmitate (Exosurf Neonatal, Burroughs Wellcome Co.) and modified bovine surfactant extract beractant (Survanta, Ross Laboratories) for the treatment of neonatal RDS. Premature infants (n = 1296) weighing 501 to 1500 g with RDS requiring assisted ventilation with 30% oxygen or more were enrolled within six hours of birth at 38 neonatal intensive care units participating in the Vermont Oxford Neonatal Network. Infants were randomly assigned to receive up to four intratracheal doses of the synthetic surfactant colfosceril palmitate (n = 644) or the modified bovine surfactant extract beractant (n = 652). The primary outcome measure was the occurrence of death or chronic lung disease (CLD) 28 days after birth. Death or CLD occurred in 57% of the infants treated with colfosceril palmitate and in 54% of those infants treated with beractant (RR 0.95; 95% CI 0.86 to 1.04). Infants with birth weights of 1001 to 1500 g who received beractant had a significantly lower risk of CLD or death at 28 days (27% vs. 34%; RR 0.78, 95% CI 0.60 to 0.99). Treatment with beractant led to significant improvement in several secondary outcome measures. Beractant treated infants received less supplemental oxygen and had lower mean airway pressures six and 72 hours after treatment. Beractant treated infants had significantly fewer pneumothoraces (9% vs. 15%; RR 0.60, 95% CI 0.44 to 0.81). There were no differences between the groups in the incidence of other neonatal complications. </p> <p><a href="./references#CD000144-bbs2-0006" title="HudakML , FarrellEE , RosenbergAA , JungAL , AutenRL , DurandDJ , et al. A multicenter randomized masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. Journal of Pediatrics1996;128(3):396‐406. ">Hudak 1996</a>: conducted a randomized controlled trial to compare the efficacy and safety of a synthetic surfactant colfosceril palmitate (Exosurf Neonatal, Burroughs Wellcome) and a surfactant extract of calf lung lavage (Infasurf, Forest Laboratories) in the treatment of neonatal RDS. Infants with RDS who were undergoing mechanical ventilation were eligible for treatment with two doses of either a synthetic or natural surfactant if the a/A O<sub>2</sub> ratio was less than or equal to 0.22. Crossover treatment was allowed within 96 hours of age if severe respiratory failure (defined as two consecutive a/A oxygen tension ratios ≤ 0.10) persisted after two doses of the randomly assigned surfactant. The trial was conducted at 21 centers. Investigators were unaware of treatment assignment. Primary outcome measures included the incidence of pulmonary air leak, the severity of RDS, the incidence of death from RDS, and the incidence of survival without BPD at 28 days after birth. The primary analysis of efficacy was performed in 1033 eligible infants and an analysis of safety outcomes in the 1126 infants who received study surfactant. Demographic characteristics and respiratory status were similar for the two treatment groups, except for a small but significant difference in mean gestational age (0.5 week) that favored the calf lung surfactant treatment group. Pulmonary air leak occurred in 21% of colfosceril palmitate treated infants and 11% of calf lung surfactant treated infants (adjusted RR 0.53; 95% CI 0.40 to 0.71). During the 72 hours after the initial surfactant treatment, infants who received calf lung surfactant had a lower average fraction of inspired oxygen and a lower average mean airway pressure. The incidence of RDS‐related death, total respiratory death, death prior to discharge, and survival without BPD at 28 days after birth did not differ. The number of days of more than 30% inspired oxygen and of assisted ventilation, but not the duration of hospitalization, were significantly lower in calf lung surfactant treated infants. </p> <p><a href="./references#CD000144-bbs2-0010" title="ModanlouHD , BeharryK , PadillaG , NorrisK , SafvatiS , ArandaJV . Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. Journal of Perinatology1997;17(6):455‐60. ">Modanlou 1997</a>: conducted a clinical trial to compare the efficacy of a synthetic surfactant colfosceril palmitate (Exosurf Neonatal, Burroughs Wellcome) and a natural surfactant extract beractant (Survanta, Ross Laboratories) on the early course of RDS, arterial blood gases, ventilator support, outcome morbidity rate, and complications of prematurity. The trial included infants treated sequentially with colfosceril palmitate (when this was the only FDA approved surfactant preparation), and infants randomly assigned to either colfosceril palmitate or beractant (once beractant became available as an approved alternative). During the randomized phase of the study 61 infants were randomly assigned to receive colfosceril palmitate and 61 infants were assigned to beractant. Although the two randomized groups were similar in severity of RDS based on FiO<sub>2</sub> and ventilator support, a significantly greater improvement in respiratory function (as evidenced by FiO<sub>2</sub>, mean airway pressure, a/A PaO<sub>2</sub> difference, and oxygen index) was observed in the beractant group from 12 hours through 48 hours. </p> <p><a href="./references#CD000144-bbs2-0012" title="MurdochE , KempleyST . Randomized trial examining cerebral haemodynamics following artificial or animal surfactant. Acta Paediatrica1998;87(4):411‐5. MurdochE , KempleyST . The effects of synthetic and natural surfactant on fluid balance in acute respiratory distress syndrome. European Journal of Pediatrics2000;159(10):767‐9 . ">Murdoch 1998</a>: Murdoch and colleagues sought to determine the effects of animal derived surfactant compared to synthetic surfactant on cerebral hemodynamics. Twenty preterm infants receiving mechanical ventilation were randomized to receive poractant alfa (Curosurf) or colfosceril palmitate (Exosurf Neonatal). Anterior cerebral artery blood flow velocity (CABFV) was measured using Doppler ultrasound before and up to two hours after treatment. Following animal surfactant treatment, there was a rapid reduction in CABF, whereas artificial surfactant resulted in a slower rise which was less marked. Animal derived surfactant produced rapid improvements in ventilation that were associated with marked alterations in cerebral haemodynamics. The only reported clinical outcomes were mortality and IVH. In a following study (Murdoch 2000), the investigators evaluated the effect of different surfactants on fluid balance. Data were collected on ventilatory parameters, daily urine output, daily weight, fluid intake and serum electrolytes. Ventilatory requirements decreased more rapidly in infants receiving animal derived surfactant, with significantly greater reductions in mean airway pressure from one to 48 hours. No other clinically relevant outcomes were reported. </p> <p><a href="./references#CD000144-bbs2-0003" title="daCostaDE , PaiMG , Al KhusaibySM . Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country. Pediatric Pulmonology1999;27(5):312‐7. ">daCosta 1999</a>: conducted a randomized clinical trial to compare the effects of a synthetic surfactant colfosceril palmitate (Exosurf Neonatal, Burroughs Wellcome) and the modified natural surfactant extract beractant (Survanta, Ross Laboratories) in infants with neonatal RDS. Eighty‐nine patients were randomly allocated to receive one of the two surfactants. Primary outcome variables included both acute and long‐term effects of the surfactant preparations, specifically the oxygenation index at 24 hours and the combined incidence of CLD or death at 28 days. Oxygenation indices in the colfosceril palmitate and beractant groups at 24 hours were similar. However, the magnitude and rapidity of responses were greater for beractant than for colfosceril palmitate. When a/A oxygen tension ratios were compared, the colfosceril palmitate group had a significantly worse a/A ratio at 24 hours than the beractant group (0.21 vs. 0.37). The combined incidence of death or CLD was not different in the two groups (18.6% colfosceril palmitate vs. 15.2% beractant). There were no statistically significant differences in the incidence of other complications of prematurity. </p> <p><a href="./references#CD000144-bbs2-0004" title="HalahakoonWL . A study of cerebral function following surfactant treatment for respiratory distress syndrome (Doctoral dissertation). Queen's University of Belfast (UK)1999. ">Halahakoon 1999</a>: As part of her PhD thesis, Halahakoon evaluated the effects of poractant alfa, beractant, and colfosceril palmitate (Exosurf Neonatal) on cerebral function, hypoxanthine levels, and antioxidant levels in 24 to 32 weeks gestation infants with RDS requiring assisted ventilation. In this single center, 39 preterm infants between 24 to 32 week gestation were randomized into three groups: poractant alfa at 100 mg/kg [n = 17, mean (SD) birth weight of 926 (278) gram, mean (SD) gestational age of 26.8 (2.4) weeks], colfosceril palmitate at 67.5 mg/kg [ n = 12, mean (SD) birth weight of 956 (233) gram, mean (SD) gestational age of 26.9 (1.9) weeks] and beractant at 100 mg/kg [n =10, mean (SD) birth weight of 1011 (327) gram, mean (SD) gestational age of 27.3 (2.0) weeks]. The study was initially designed to compare only two surfactants (poractant alfa and colfosceril palmitate) and later included beractant, hence differences in number of patients in each group. For purposes of this review, infants randomized to "any animal derived surfactant" (poractant alfa or beractant) was compared to the synthetic surfactant colfosceril palmitate. Method of randomization and any attempt for blinding was not reported. Envelopes were used for allocation concealment. </p> <p><a href="./references#CD000144-bbs2-0009" title="LloydJ , ToddDA , JohnE . Serial phospholipid analysis in preterm infants: comparison of Exosurf and Survanta. Early Human Development1999;54(2):157‐68. ">Lloyd 1999</a>: conducted a study to determine the phospholipid composition of lung aspirates in infants that received colfosceril palmitate (Exosurf), an artificial surfactant, or beractant (Survanta), an animal derived surfactant, compared to an untreated control group of infants with 'normal lungs'. Infants less than 32 weeks gestation with RDS were randomly assigned to receive either colfosceril palmitate or beractant. Endotracheal or hypopharyngeal aspirates were obtained from these infants and from the control infants to determine the phospholipid composition of the lung fluid. The aspirates were taken prior to and up to 28 days following surfactant administration. The different phospholipids were separated by thin layer chromatography and expressed as a per cent of total phospholipid measured. </p> <p>Infants with 'normal lungs' had a higher proportion of phosphatidylcholine prior to treatment than those with RDS. The infants with 'normal lungs' had a greater proportion of phosphatidylinositol in their lung aspirates than both treatment groups at 24 hours. Infants in the beractant group had a higher proportion of phosphatidylglycerol at 48 hours than the group with 'normal lungs'. No other differences were found in phospholipid composition up to 28 days. There were no major differences in the phospholipid profile in infants with RDS treated with either colfosceril palmitate or beractant. </p> <p>Infants that received colfosceril palmitate had increased mean airway pressure and oxygen requirements at 24 hours when compared to beractant (8.1 cmH<sub>2</sub>O vs. 7.7 cmH<sub>2</sub>O, P &lt; 0.02 and 34% vs. 28%, P &lt; 0.006 respectively). The incidence of CLD at 36 weeks postconceptual age was not statistically significant between the groups. Neither the clinical differences initially seen between infants treated with colfosceril palmitate or beractant nor the long‐term outcomes could be explained by the phospholipid composition of serial samples of lung aspirates. </p> <p><a href="./references#CD000144-bbs2-0001" title="AinsworthSB , BeresfordMW , MilliganDW , ShawNJ , MatthewsJN , FentonAC , et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25‐29 weeks' gestation: a randomised trial. Lancet2000;355(9213):1387‐92. ">Ainsworth 2000</a>: conducted a randomized controlled trial to compare a synthetic surfactant (pumactant, Britannia Pharmaceuticals) with a natural porcine surfactant (poractant alfa, Curosurf). Two hundred and twelve neonates born between 25 weeks and 29 weeks and six days gestation who required intubation were randomly assigned to poractant alfa (n = 105) or pumactant (n = 107). Outcome data were analyzed for 199 babies. The trial was stopped on the recommendation of the data and safety monitoring committee because of concern regarding increased mortality in the group receiving synthetic surfactant (poractant alfa 14% vs. pumactant 31%; odds ratio 0.37; 95% CI 0.18 to 0.76). This difference was sustained after adjustment for center, gestation, birth weight, sex, plurality, and use of antenatal steroids. </p> <p><a href="./references#CD000144-bbs2-0008" title="KukkonenAK , VirtanenM , JarvenpaaAL , PokelaML , IkonenS , FellmanV . Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?. Acta Paediatrica2000;89(5):556‐61. ">Kukkonen 2000</a>: conducted a randomized controlled trial to compare the efficacy of a natural porcine surfactant (poractant, Curosurf) and the synthetic surfactant colfosceril palmitate (Exosurf Neonatal, Burroughs Wellcome). In three neonatal intensive care units, 228 neonates with respiratory distress and an a/A O<sub>2</sub> ratio &lt; 0.22 were randomly assigned to receive either poractant (100 mg/kg) or colfosceril palmitate (5 ml/kg). After poractant, the FiO<sub>2</sub> was lower from 15 min (0.45 ± 0.22 vs. 0.70 ± 0.22, P = 0.0001) to six hours (0.48 ± 0.26 vs. 0.64 ± 0.23, P = 0.0001) and the mean airway pressure was lower at one hour (8.3 ± 3.2 mm H<sub>2</sub>O vs. 9.4 ± 3.1 mm H<sub>2</sub>O, P = 0.01). Thereafter, the respiratory parameters were similar. The duration of mechanical ventilation (median six vs. five days) and the duration of oxygen supplementation (median five vs. four days) were similar for poractant and colfosceril palmitate. An increased risk of bacteremia was associated with poractant treatment (11% vs. 4%; RR 3.17, 95% CI 1.05 to 9.52). </p> </section> <section id="CD000144-sec-0062"> <h4 class="title">Summary</h4> </section> <section id="CD000144-sec-0063"> <h4 class="title"><i>Timing of treatment</i> </h4> <p><a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> reported a comparison of calf lung derived surfactant and colfosceril palmitate in the context of prophylactic surfactant administration. <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> compared colfosceril palmitate, lucinactant or beractant administered within 20 to 30 minutes after birth. All other studies treated infants with signs and symptoms of RDS. <a href="./references#CD000144-bbs2-0001" title="AinsworthSB , BeresfordMW , MilliganDW , ShawNJ , MatthewsJN , FentonAC , et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25‐29 weeks' gestation: a randomised trial. Lancet2000;355(9213):1387‐92. ">Ainsworth 2000</a> treated infants requiring intubation for "presumed surfactant deficiency". These infants could be treated within 30 minutes of age. Other treatment studies relied on evidence of established RDS. </p> </section> <section id="CD000144-sec-0064"> <h4 class="title"><i>Entry criteria</i> </h4> <p>In his prevention trial, <a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> attempted to enroll infants at high risk of developing RDS. Enrolled infants were less than 29 weeks gestation. <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> enrolled at risk infants between 24 and 32 weeks gestation with birth weights between 600 and 1250 g that had undergone endotracheal intubation. </p> <p>In the treatment trials, <a href="./references#CD000144-bbs2-0002" title="AlvaradoM , HingreR , HakasonD , GrossS . Clinical trial of survanta versus exosurf in infants &lt; 1500g with respiratory distress syndrome. Pediatric Research1993;33:314A. ">Alvarado 1993</a>, <a href="./references#CD000144-bbs2-0005" title="HorbarJD , WrightLL , SollRF , WrightEC , FanaroffAA , KoronesSB , et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. Journal of Pediatrics1993;123(5):757‐66. ">Horbar 1993</a>, <a href="./references#CD000144-bbs2-0015" title="The Vermont Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics1996;97(1):1‐6. ">VT Oxford 1996</a> and <a href="./references#CD000144-bbs2-0010" title="ModanlouHD , BeharryK , PadillaG , NorrisK , SafvatiS , ArandaJV . Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. Journal of Perinatology1997;17(6):455‐60. ">Modanlou 1997</a> all studied infants with birth weight &lt; 1500 g. The trials of <a href="./references#CD000144-bbs2-0006" title="HudakML , FarrellEE , RosenbergAA , JungAL , AutenRL , DurandDJ , et al. A multicenter randomized masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. Journal of Pediatrics1996;128(3):396‐406. ">Hudak 1996</a> and <a href="./references#CD000144-bbs2-0013" title="PearlmanSA , LeefKH , StefanoJL , et al. A randomized trial comparing Exosurf versus Survanta in the treatment of neonatal RDS. Pediatric Research1993;33:340A. ">Pearlman 1993</a> studied premature infants without a specific birth weight limitation. <a href="./references#CD000144-bbs2-0014" title="SehgalSS , EwingCK , RichardsT , TaeuschHW . Modified bovine surfactant (Survanta) versus a protein free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. Journal of the National Medical Association1994;86(1):46‐52. ">Sehgal 1994</a> studied infants between birth weights 600 to 1750 g. Ainsworth studied infants born between 25 and 29 + 6 weeks gestation. All studies required that the infants be on assisted ventilation and have RDS. <a href="./references#CD000144-bbs2-0001" title="AinsworthSB , BeresfordMW , MilliganDW , ShawNJ , MatthewsJN , FentonAC , et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25‐29 weeks' gestation: a randomised trial. Lancet2000;355(9213):1387‐92. ">Ainsworth 2000</a> required only the clinician's assessment that the infant required intubation and had signs of respiratory distress. In other treatment studies, a variety of criteria for oxygen requirement at entry were used. <a href="./references#CD000144-bbs2-0002" title="AlvaradoM , HingreR , HakasonD , GrossS . Clinical trial of survanta versus exosurf in infants &lt; 1500g with respiratory distress syndrome. Pediatric Research1993;33:314A. ">Alvarado 1993</a> and <a href="./references#CD000144-bbs2-0003" title="daCostaDE , PaiMG , Al KhusaibySM . Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country. Pediatric Pulmonology1999;27(5):312‐7. ">daCosta 1999</a> required that infants be on supplemental oxygen &gt; 40%. The study of <a href="./references#CD000144-bbs2-0005" title="HorbarJD , WrightLL , SollRF , WrightEC , FanaroffAA , KoronesSB , et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. Journal of Pediatrics1993;123(5):757‐66. ">Horbar 1993</a> and the <a href="./references#CD000144-bbs2-0015" title="The Vermont Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics1996;97(1):1‐6. ">VT Oxford 1996</a> study required that infants be on supplemental oxygen &gt; 30%. <a href="./references#CD000144-bbs2-0006" title="HudakML , FarrellEE , RosenbergAA , JungAL , AutenRL , DurandDJ , et al. A multicenter randomized masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. Journal of Pediatrics1996;128(3):396‐406. ">Hudak 1996</a>, <a href="./references#CD000144-bbs2-0010" title="ModanlouHD , BeharryK , PadillaG , NorrisK , SafvatiS , ArandaJV . Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. Journal of Perinatology1997;17(6):455‐60. ">Modanlou 1997</a>, and <a href="./references#CD000144-bbs2-0008" title="KukkonenAK , VirtanenM , JarvenpaaAL , PokelaML , IkonenS , FellmanV . Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?. Acta Paediatrica2000;89(5):556‐61. ">Kukkonen 2000</a> required that infants demonstrate an a/A oxygen ratio of less than or equal to 0.22. This corresponded to being on approximately 40% supplemental oxygen. A variety of age criteria were set out by investigators. In the treatment trials, age at entry varied from within 30 minutes of birth (<a href="./references#CD000144-bbs2-0001" title="AinsworthSB , BeresfordMW , MilliganDW , ShawNJ , MatthewsJN , FentonAC , et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25‐29 weeks' gestation: a randomised trial. Lancet2000;355(9213):1387‐92. ">Ainsworth 2000</a>) to 72 hours of age (<a href="./references#CD000144-bbs2-0006" title="HudakML , FarrellEE , RosenbergAA , JungAL , AutenRL , DurandDJ , et al. A multicenter randomized masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. Journal of Pediatrics1996;128(3):396‐406. ">Hudak 1996</a>). </p> </section> <section id="CD000144-sec-0065"> <h4 class="title"><i>Surfactant preparation</i> </h4> <p>In 12 of the included studies, the synthetic surfactant studied was colfosceril palmitate (Exosurf Neonatal, Burroughs Wellcome), a synthetic surfactant containing colfosceril palmitate, cetyl alcohol and tyloxapol. <a href="./references#CD000144-bbs2-0001" title="AinsworthSB , BeresfordMW , MilliganDW , ShawNJ , MatthewsJN , FentonAC , et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25‐29 weeks' gestation: a randomised trial. Lancet2000;355(9213):1387‐92. ">Ainsworth 2000</a> studied pumactant (Britannia Pharmaceuticals), a synthetic surfactant composed of dipalmitoyl phosphatidylcholine and phosphatidylglycerol. In eight of the studies, the animal derived surfactant extract tested was beractant (Survanta, Ross Laboratories), a modified bovine surfactant extract. <a href="./references#CD000144-bbs2-0006" title="HudakML , FarrellEE , RosenbergAA , JungAL , AutenRL , DurandDJ , et al. A multicenter randomized masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. Journal of Pediatrics1996;128(3):396‐406. ">Hudak 1996</a> and <a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> studied the bovine surfactant Infasurf (Forest Laboratories). Infasurf is obtained from lavage of calf lung. Unlike beractant, no supplemental lipids are added to this formulation. <a href="./references#CD000144-bbs2-0001" title="AinsworthSB , BeresfordMW , MilliganDW , ShawNJ , MatthewsJN , FentonAC , et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25‐29 weeks' gestation: a randomised trial. Lancet2000;355(9213):1387‐92. ">Ainsworth 2000</a> and <a href="./references#CD000144-bbs2-0008" title="KukkonenAK , VirtanenM , JarvenpaaAL , PokelaML , IkonenS , FellmanV . Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?. Acta Paediatrica2000;89(5):556‐61. ">Kukkonen 2000</a> studied the porcine surfactant poractant. </p> </section> <section id="CD000144-sec-0066"> <h4 class="title"><i>Study outcomes</i> </h4> <p>The majority of studies included initial clinical improvement as well as a variety of complications of prematurity including pneumothorax, patent ductus arteriosus (PDA), pulmonary hemorrhage, necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), chronic lung disease (CLD), and mortality. This analysis focused on the major clinical outcomes described in these studies. </p> </section> </section> <section id="CD000144-sec-0067"> <h3 class="title">Risk of bias in included studies</h3> <p>Only randomized clinical trials which compared the effects of non‐protein containing synthetic surfactant to animal derived surfactant extract in preterm infants at risk for or having RDS were included in the analyses. Twenty‐two potentially relevant trials were identified. Eight trials were excluded from the final analysis. The studies of <a href="./references#CD000144-bbs2-0018" title="CottonRB , LawAB , LindstromDP , et al. Differential effects of synthetic and bovine surfactants on lung volume and oxygenation in premature infants with RDS [abstract]. Pediatric Research1992;31:304A. ">Cotton 1992</a>, <a href="./references#CD000144-bbs2-0020" title="RollinsM , JenkinsJ , TubmanR , CorkeyC , WilsonD . Comparison of clinical responses to natural and synthetic surfactants. Journal of Perinatal Medicine1993;21(5):341‐7. ">Rollins 1993</a>, <a href="./references#CD000144-bbs2-0023" title="StensonBJ , GloverRM , PappyGJ , WilkieRA , LaingIA , Tarnow‐MordiWO . Static respiratory compliance in the newborn. III. Early changes after exogenous surfactant treatment. Archives of Disease in Childhood1994;70(1):F19‐24. ">Stenson 1994</a>, and <a href="./references#CD000144-bbs2-0021" title="SanghviKP , MerchantRH . Single dose surfactant rescue therapy in neonatal respiratory distress syndrome. Indian Pediatrics1998;35(6):533‐6. ">Sanghvi 1998</a> were excluded because they were not randomized trials. <a href="./references#CD000144-bbs2-0019" title="GrauaugA , KohanR , SlyP , et al. Are there advantages of one over the other when used as rescue therapy [abstract]. Pediatric Research1994;35:335A. ">Grauaug 1994</a>, <a href="./references#CD000144-bbs2-0017" title="ChoukrounML , LlanasB , ApereH , FayonM , GalperineRI , GuenardH , et al. Pulmonary mechanics in ventilated preterm infants with respiratory distress syndrome after exogenous surfactant administration: A comparison between two surfactant preparations. Pediatric Pulmonology1994;18(5):273‐8. ">Choukroun 1994</a>, and <a href="./references#CD000144-bbs2-0016" title="BassiounyMR , RemoC , CherianE . Comparison of the changes in the a/A oxygen ratio after administration of two surfactants for the treatment of neonatal respiratory distress syndrome. Journal of Tropical Pediatrics1997;43(1):38‐41. ">Bassiouny 1997</a> did not present relevant clinical outcomes for inclusion in the analysis. <a href="./references#CD000144-bbs2-0022" title="SinhaSK , Lacaze‐MasmonteilT , Vallsi Soler A , WiswellTE , GadzinowskiJ , HadjuJ , et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa in very premature infants at high risk for respiratory distress syndrome. Pediatrics2005;115(4):1030‐8. ">Sinha 2005</a> compared animal derived surfactant to protein containing synthetic surfactant. The remaining 14 studies were either random or quasi‐random in treatment assignment and reported on at least one relevant clinical outcome. </p> <section id="CD000144-sec-0068"> <h4 class="title">Methods of randomization</h4> <p>The methods of randomization were specified in 10 of the studies. <a href="./references#CD000144-bbs2-0014" title="SehgalSS , EwingCK , RichardsT , TaeuschHW . Modified bovine surfactant (Survanta) versus a protein free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. Journal of the National Medical Association1994;86(1):46‐52. ">Sehgal 1994</a>, <a href="./references#CD000144-bbs2-0006" title="HudakML , FarrellEE , RosenbergAA , JungAL , AutenRL , DurandDJ , et al. A multicenter randomized masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. Journal of Pediatrics1996;128(3):396‐406. ">Hudak 1996</a>, <a href="./references#CD000144-bbs2-0015" title="The Vermont Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics1996;97(1):1‐6. ">VT Oxford 1996</a>, <a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a>, <a href="./references#CD000144-bbs2-0003" title="daCostaDE , PaiMG , Al KhusaibySM . Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country. Pediatric Pulmonology1999;27(5):312‐7. ">daCosta 1999</a>, <a href="./references#CD000144-bbs2-0004" title="HalahakoonWL . A study of cerebral function following surfactant treatment for respiratory distress syndrome (Doctoral dissertation). Queen's University of Belfast (UK)1999. ">Halahakoon 1999</a>, and <a href="./references#CD000144-bbs2-0008" title="KukkonenAK , VirtanenM , JarvenpaaAL , PokelaML , IkonenS , FellmanV . Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?. Acta Paediatrica2000;89(5):556‐61. ">Kukkonen 2000</a> all used sealed envelopes opened by the clinical investigators. <a href="./references#CD000144-bbs2-0005" title="HorbarJD , WrightLL , SollRF , WrightEC , FanaroffAA , KoronesSB , et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. Journal of Pediatrics1993;123(5):757‐66. ">Horbar 1993</a> used randomization lists at study center pharmacies. <a href="./references#CD000144-bbs2-0010" title="ModanlouHD , BeharryK , PadillaG , NorrisK , SafvatiS , ArandaJV . Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. Journal of Perinatology1997;17(6):455‐60. ">Modanlou 1997</a> used shuffled color‐coded cards. <a href="./references#CD000144-bbs2-0001" title="AinsworthSB , BeresfordMW , MilliganDW , ShawNJ , MatthewsJN , FentonAC , et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25‐29 weeks' gestation: a randomised trial. Lancet2000;355(9213):1387‐92. ">Ainsworth 2000</a> had a central telephone randomization system. <a href="./references#CD000144-bbs2-0013" title="PearlmanSA , LeefKH , StefanoJL , et al. A randomized trial comparing Exosurf versus Survanta in the treatment of neonatal RDS. Pediatric Research1993;33:340A. ">Pearlman 1993</a> used a quasi‐randomized strategy allowing for alternate month treatment. The randomization methods used by <a href="./references#CD000144-bbs2-0002" title="AlvaradoM , HingreR , HakasonD , GrossS . Clinical trial of survanta versus exosurf in infants &lt; 1500g with respiratory distress syndrome. Pediatric Research1993;33:314A. ">Alvarado 1993</a> were not specified. <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> randomized all patients after birth in a masked manner using sealed envelopes with randomization codes stratified according to birth weight (600 to 800 g, 801 to 1000 g, or 1001 to 1250 g) that were computer generated by an independent, university based, statistical analysis center. Envelopes were opened sequentially as each new patient was randomized (<a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a>). Infants were randomized to receive lucinactant, colfosceril palmitate, or beractant in a 2:2:1 ratio (<a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a>). </p> </section> <section id="CD000144-sec-0069"> <h4 class="title">Blinding</h4> <p>In both the prevention and treatment trials of the animal derived surfactant Infasurf (<a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a>), investigators not involved in clinical care administered the surfactant. In the trial of <a href="./references#CD000144-bbs2-0002" title="AlvaradoM , HingreR , HakasonD , GrossS . Clinical trial of survanta versus exosurf in infants &lt; 1500g with respiratory distress syndrome. Pediatric Research1993;33:314A. ">Alvarado 1993</a> investigators were "blinded" to treatment assignment; however, the methods of masking treatment were not described. In the other trials, treatment concealment was not attempted. </p> </section> </section> <section id="CD000144-sec-0070"> <h3 class="title" id="CD000144-sec-0070">Effects of interventions</h3> <p><b>Animal derived surfactant extract versus protein free synthetic surfactant (Comparison 1)</b> </p> <p>Each of the studies comparing animal derived surfactant extract to synthetic surfactant reported greater improvement in the immediate need for respiratory support associated with treatment with animal derived surfactant extract. Relevant clinical outcomes are noted below. </p> <section id="CD000144-sec-0071"> <h4 class="title">Primary outcome measures</h4> <p><b>Mortality (Outcome 1.1)</b>(<a href="#CD000144-fig-0001">Figure 1</a>): </p> <div class="figure" id="CD000144-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.1 Mortality." data-id="CD000144-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.1 Mortality. </p> </div> </div> </div> <section id="CD000144-sec-0072"> <h5 class="title">Prevention trials</h5> <p><a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> reported no decrease in the risk of mortality associated with the prophylactic use of animal derived surfactant (RR 0.88, 95% CI 0.64 to 1.19; RD ‐0.02, 95% CI ‐0.07 to 0.03). <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> did not find a significant increase in the risk of mortality with either surfactant preparation (RR 0.97, 95% CI 0.77 to 1.23; RD ‐0.01, 95% CI ‐0.08 to 0.06). Meta‐analysis of the prevention trials did not support an increase in mortality risk for either surfactant preparation (typical RR 0.93, 95% CI 0.77 to 1.13; typical RD ‐0.02, CI 95% ‐0.06 to 0.03; 2 studies, 1613 infants). </p> </section> <section id="CD000144-sec-0073"> <h5 class="title">Treatment trials</h5> <p><a href="./references#CD000144-bbs2-0001" title="AinsworthSB , BeresfordMW , MilliganDW , ShawNJ , MatthewsJN , FentonAC , et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25‐29 weeks' gestation: a randomised trial. Lancet2000;355(9213):1387‐92. ">Ainsworth 2000</a> reported a decreased risk of mortality associated with animal derived surfactant extract treatment. For the treatment trials, the meta‐analyses supported a marginal reduction in the risk of mortality (typical RR 0.86, 95% CI 0.75 to 0.99; typical RD ‐0.03, 95% CI ‐0.05 to ‐0.00; 11 studies, 3800 infants). </p> <p>Overall, the meta‐analyses supported a marginal reduction in the risk of mortality (typical RR 0.89, 95% CI 0.79 to 0.99; typical RD ‐0.02, 95% CI ‐0.04 to ‐0.00; 13 studies, 5413 infants). </p> <p><b>Bronchopulmonary dysplasia (BPD) (oxygen requirement at 28 days of life) (Outcome 1.2)</b>(<a href="#CD000144-fig-0002">Figure 2</a>): </p> <div class="figure" id="CD000144-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.2 Bronchopulmonary dysplasia." data-id="CD000144-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.2 Bronchopulmonary dysplasia. </p> </div> </div> </div> </section> <section id="CD000144-sec-0074"> <h5 class="title">Prevention trials</h5> <p><a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> reported no significant effect of surfactant preparation on the risk of BPD (RR 1.05, 95% CI 0.76 to 1.46; RD 0.01, 95% CI ‐0.04 to 0.05). <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> did not support a significant effect of surfactant preparation on BPD (RR 0.93, 95% CI 0.82 to 1.05; RD ‐0.04, 95% CI ‐0.12 to 0.03). Meta‐analysis of the prophylactic studies did not demonstrate a significant effect of surfactant preparation on BPD (typical RR 0.96, 95% CI 0.85 to 1.08; typical RD ‐0.02, 95% CI ‐0.06 to 0.03; 2 studies, 1613 infants). </p> </section> <section id="CD000144-sec-0075"> <h5 class="title">Treatment trials</h5> <p>None of the eight treatment trials that reported on the incidence of BPD noted an effect of surfactant preparation on the risk of BPD. The meta‐analysis of the treatment studies demonstrated no effect of surfactant preparation on the risk of BPD (typical RR 1.02, 95% CI 0.93 to 1.11; typical RD 0.01, 95% CI ‐0.03 to 0.04; 8 studies, 2798 infants). </p> <p>Overall, the meta‐analyses supported no significant effect of surfactant preparation on the risk of BPD (typical RR 1.00, 95% CI 0.93 to 1.07; typical RD 0, 95% CI ‐0.03 to 0.03; 10 studies, 4321 infants). </p> <p><b>Chronic lung disease (CLD) (oxygen requirement at 36 weeks adjusted age) (Outcome 1.3)</b>(<a href="#CD000144-fig-0003">Figure 3</a>): </p> <div class="figure" id="CD000144-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.3 Chronic lung disease." data-id="CD000144-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.3 Chronic lung disease. </p> </div> </div> </div> </section> <section id="CD000144-sec-0076"> <h5 class="title">Prevention trials</h5> <p><a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> reported no significant effect of surfactant preparation on the risk of CLD (RR 1.09, 95% CI 0.90 to 1.31; RD 0.03, 95% CI ‐0.03 to 0.09). Prophylactic administration of either protein free synthetic surfactant or animal derived surfactant did not affect the risk of CLD in the <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> trial (RR 0.94, 95% CI 0.79 to 1.12; RD ‐0.03, 95% CI ‐0.10 to 0.05). Meta‐analysis of the prevention trials did not demonstrate any impact on the risk of CLD based on surfactant preparation (typical RR 1.01, CI 95% 0.89 to 1.15; typical RD 0.00, 95% CI ‐0.04 to 0.05; 2 studies, 1609 infants). </p> </section> <section id="CD000144-sec-0077"> <h5 class="title">Treatment trials</h5> <p>None of the five treatment trials that reported on the incidence of CLD noted an effect of surfactant preparation on the risk of CLD. The meta‐analysis of the treatment studies demonstrated no effect of surfactant preparation on the risk of CLD (typical RR 0.98, 95% CI 0.86 to 1.11; typical RD ‐0.01, 95% CI ‐0.04 to 0.03; 6 studies, 2418 infants). </p> <p>Overall, the meta‐analyses supported no statistically significant effect of surfactant preparation on the risk of CLD (typical RR 0.99, 95% CI 0.91 to 1.09; typical RD 0.00, 95% CI ‐0.03 to 0.03; 8 studies, 4027 infants). </p> </section> <section id="CD000144-sec-0078"> <h5 class="title">Bronchopulmonary dysplasia (BPD) or death (Outcome 1.4):</h5> <section id="CD000144-sec-0079"> <h6 class="title">Prevention trials</h6> <p><a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> reported no statistically significant effect of surfactant preparation on the risk of BPD or mortality (RR 0.98, 95% CI 0.91 to 1.06; RD ‐0.01, 95% CI ‐0.07 to 0.04). <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> did not support an increase in the risk of BPD or mortality for either surfactant preparation (RR 0.94, 95% CI 0.83 to 1.06; RD ‐0.04, 95% CI ‐0.11 to 0.04). Meta‐analysis of the prevention trials did not demonstrate an increased risk of BPD or mortality (typical RR 0.96, 95% CI 0.90 to 1.03; typical RD ‐0.02, 95% CI ‐0.07 to 0.02). </p> </section> <section id="CD000144-sec-0080"> <h6 class="title">Treatment trials</h6> <p>None of the four trials that reported on the incidence of BPD or mortality noted an effect of surfactant preparation on the risk of BPD or mortality. The meta‐analysis of the treatment studies demonstrated no effect of surfactant preparation on the risk of BPD or mortality (typical RR 0.94, 95% CI 0.88 to 1.01; typical RD ‐0.03, 95% CI ‐0.08 to 0.01). </p> <p>Overall, the meta‐analyses supported a marginal decrease in the risk of BPD or mortality associated with the use of animal derived surfactant preparations (typical RR 0.95, 95% CI 0.91 to 1.00; typical RD ‐0.03, 95% CI ‐0.06 to 0.00). </p> </section> </section> <section id="CD000144-sec-0081"> <h5 class="title">Chronic lung disease (CLD) or mortality (Outcome 1.5):</h5> <section id="CD000144-sec-0082"> <h6 class="title">Prevention trials</h6> <p><a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> reported no significant effect of surfactant preparation on the risk of the combined outcome of CLD or mortality (RR 1.02, 95% CI 0.89 to 1.16; RD 0.01, 95% CI ‐0.06 to 0.08). <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> did not report any significant effect of surfactant preparation on the combined outcome of CLD or mortality (RR 0.95, 95% CI 0.80 to 1.12; RD ‐0.02, 95% CI ‐0.10 to 0.05). Meta‐analysis of the prevention trials did not demonstrate a significant increase in the risk of CLD or mortality with either synthetic or naturally derived surfactant preparations (typical RR 0.99, 95% CI 0.89 to 1.10; typical RD ‐0.01, 95% CI ‐0.06 to 0.04). </p> </section> <section id="CD000144-sec-0083"> <h6 class="title">Treatment trials</h6> <p><a href="./references#CD000144-bbs2-0008" title="KukkonenAK , VirtanenM , JarvenpaaAL , PokelaML , IkonenS , FellmanV . Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?. Acta Paediatrica2000;89(5):556‐61. ">Kukkonen 2000</a> noted a marginal increase in the risk of the combined outcome of CLD or mortality (RR 1.35, 95% CI 1.00 to 1.82; RD 0.13, 95% CI 0.00 to 0.26); whereas the Vermont Oxford Trial (<a href="./references#CD000144-bbs2-0015" title="The Vermont Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics1996;97(1):1‐6. ">VT Oxford 1996</a>) noted a marginal decrease (RR 0.89, 95% CI 0.78 to 1.01; RD ‐0.05, 95% CI ‐0.10 to 0.00). The meta‐analysis of the treatment studies demonstrated no effect of surfactant preparation on the risk of CLD or mortality (typical RR 0.95, 95% CI 0.86 to 1.06; typical RD ‐0.02, 95% CI ‐0.07 to 0.02). </p> <p>Overall, the meta‐analyses supported no significant effect of surfactant preparation on the risk of the combined outcome of CLD and mortality (typical RR 0.97, 95% CI 0.90 to 1.04; typical RD ‐0.01, 95% CI ‐0.05 to 0.02). </p> </section> </section> </section> <section id="CD000144-sec-0084"> <h4 class="title">Secondary outcome measures</h4> <p><b>Pneumothorax (Outcome 1.6)</b>(<a href="#CD000144-fig-0004">Figure 4</a>): </p> <div class="figure" id="CD000144-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.6 Pneumothorax." data-id="CD000144-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.6 Pneumothorax. </p> </div> </div> </div> <section id="CD000144-sec-0085"> <h5 class="title">Prevention trials</h5> <p>Hudak (<a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a>) reported no difference in the risk of pneumothorax associated with the prophylactic use of animal derived surfactant (RR 0.62, 95% CI 0.34 to 1.13; RD ‐0.02, 95% CI ‐0.05 to 0.01). Moya and colleagues (<a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a>) did not report any significant difference in pneumothorax (RR 0.79, 95% CI 0.43 to 1.44; RD ‐0.01, 95% CI ‐0.05 to 0.02). The meta‐analysis of both of these prophylactic trials (<a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a>; <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a>) did not show any significant difference in the risk of pneumothorax between the different surfactant preparations (typical RR 0.70, 95% CI 0.46 to 1.07; typical RD ‐0.02, 95% CI ‐0.04 to 0.00; 2 studies, 1613 infants). </p> </section> <section id="CD000144-sec-0086"> <h5 class="title">Treatment trials</h5> <p><a href="./references#CD000144-bbs2-0006" title="HudakML , FarrellEE , RosenbergAA , JungAL , AutenRL , DurandDJ , et al. A multicenter randomized masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. Journal of Pediatrics1996;128(3):396‐406. ">Hudak 1996</a>, <a href="./references#CD000144-bbs2-0015" title="The Vermont Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics1996;97(1):1‐6. ">VT Oxford 1996</a>, and <a href="./references#CD000144-bbs2-0001" title="AinsworthSB , BeresfordMW , MilliganDW , ShawNJ , MatthewsJN , FentonAC , et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25‐29 weeks' gestation: a randomised trial. Lancet2000;355(9213):1387‐92. ">Ainsworth 2000</a> reported a decreased incidence of pneumothorax associated with animal derived surfactant extract treatment. For the treatment trials, the meta‐analyses supported a significant reduction in the risk of pneumothorax (typical RR 0.64, 95% CI 0.53 to 0.77; typical RD ‐0.05, 95% CI ‐0.07 to ‐0.03; 9 studies, 3743 infants). </p> <p>Overall, the meta‐analyses supported a significant reduction in the risk of pneumothorax (typical RR 0.65, 95% CI 0.55 to 0.77; typical RD ‐0.04, 95% CI ‐0.06 to ‐0.02; NNT 25; 11 studies, 5356 infants). </p> </section> <section id="CD000144-sec-0087"> <h5 class="title">Patent ductus arteriosus (PDA) (Outcome 1.7):</h5> <section id="CD000144-sec-0088"> <h6 class="title">Prevention trials</h6> <p><a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> reported no significant effect of surfactant preparation on the risk of PDA (RR 0.97, 95% CI 0.85 to 1.09; RD ‐0.02, 95% CI ‐0.09 to 0.05; 1 study, 846 infants). <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> did not report on the incidence of PDA in either the animal derived surfactant or non‐protein synthetic surfactant groups. </p> </section> <section id="CD000144-sec-0089"> <h6 class="title">Treatment trials</h6> <p><a href="./references#CD000144-bbs2-0001" title="AinsworthSB , BeresfordMW , MilliganDW , ShawNJ , MatthewsJN , FentonAC , et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25‐29 weeks' gestation: a randomised trial. Lancet2000;355(9213):1387‐92. ">Ainsworth 2000</a> reported a marginal increase in the risk of PDA associated with animal derived surfactant extract treatment (RR 2.02, 95% CI 1.00 to 4.09; RD 0.10, 95% CI 0.00 to 0.20). For the treatment trials, the meta‐analysis demonstrated no effect of surfactant preparation on the risk of PDA (typical RR 0.99, 95% CI 0.90 to 1.08; typical RD ‐0.01, 95% CI ‐0.04 to 0.03; 7 studies, 2476 infants). </p> <p>Overall, the meta‐analyses supported no significant effect of surfactant preparation on the risk of PDA (typical RR 0.98, 95% CI 0.91 to 1.05; typical RD ‐0.01, 95% CI ‐0.04 to 0.02; 8 studies, 3322 infants). </p> </section> </section> <section id="CD000144-sec-0090"> <h5 class="title">Sepsis (Outcome 1.8):</h5> <section id="CD000144-sec-0091"> <h6 class="title">Prevention trials</h6> <p>Neither the trial of <a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> (RR 1.13, 95% CI 0.92 to 1.39; RD 0.04, 95% CI ‐0.02 to 0.10) nor the trial of <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> (RR 0.99, 95% CI 0.84 to 1.17; RD 0.00, 95% CI ‐0.08 to 0.07) reported a significant effect of surfactant preparation on the risk of sepsis. The meta‐analysis did not reveal an association of surfactant preparation and risk of sepsis (typical RR 1.05, 95% CI 0.92 to 1.20; typical RD 0.02, 95% CI ‐0.03 to 0.07; 2 studies, 1613 infants). </p> </section> <section id="CD000144-sec-0092"> <h6 class="title">Treatment trials</h6> <p>Heterogeneous results were noted in the treatment trials. <a href="./references#CD000144-bbs2-0006" title="HudakML , FarrellEE , RosenbergAA , JungAL , AutenRL , DurandDJ , et al. A multicenter randomized masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. Journal of Pediatrics1996;128(3):396‐406. ">Hudak 1996</a> noted a decreased risk of sepsis associated with animal derived surfactant treatment (RR 0.71, 95% CI 0.52 to 0.96; RD ‐0.05, 95% CI ‐0.09 to ‐0.01). <a href="./references#CD000144-bbs2-0008" title="KukkonenAK , VirtanenM , JarvenpaaAL , PokelaML , IkonenS , FellmanV . Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?. Acta Paediatrica2000;89(5):556‐61. ">Kukkonen 2000</a> reported an increase in the risk of sepsis associated with animal derived surfactant extract treatment (RR 3.17, 95% CI 1.05 to 9.52; RD 0.08, 95% CI 0.01 to 0.15). For the treatment trials, no overall effect of surfactant preparation on the risk of sepsis was noted (typical RR 0.96, 95% CI 0.85 to 1.09; typical RD ‐0.01, 95% CI ‐0.03 to 0.02; 8 studies, 3606 infants). </p> <p>Overall, the meta‐analyses supported no significant effect of surfactant preparation on the risk of sepsis (typical RR 1.00, 95% CI 0.91 to 1.10; typical RD 0.00, 95% CI ‐0.02 to 0.02; 10 studies, 5219 infants). </p> </section> </section> <section id="CD000144-sec-0093"> <h5 class="title">Necrotizing enterocolitis (NEC) (Bell's stage II or greater) (Outcome 1.9):</h5> <section id="CD000144-sec-0094"> <h6 class="title">Prevention trials</h6> <p>Hudak (<a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a>) reported no difference in the risk of NEC associated with the prophylactic use of animal derived surfactant compared to protein free synthetic surfactant (RR 1.39, 95% CI 0.83 to 2.34; RD 0.02, 95% CI ‐0.01 to 0.05; 1 study, 846 infants). </p> </section> <section id="CD000144-sec-0095"> <h6 class="title">Treatment trials</h6> <p>Six of the treatment trials reported on NEC (<a href="./references#CD000144-bbs2-0005" title="HorbarJD , WrightLL , SollRF , WrightEC , FanaroffAA , KoronesSB , et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. Journal of Pediatrics1993;123(5):757‐66. ">Horbar 1993</a>; <a href="./references#CD000144-bbs2-0013" title="PearlmanSA , LeefKH , StefanoJL , et al. A randomized trial comparing Exosurf versus Survanta in the treatment of neonatal RDS. Pediatric Research1993;33:340A. ">Pearlman 1993</a>; <a href="./references#CD000144-bbs2-0015" title="The Vermont Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics1996;97(1):1‐6. ">VT Oxford 1996</a>; <a href="./references#CD000144-bbs2-0010" title="ModanlouHD , BeharryK , PadillaG , NorrisK , SafvatiS , ArandaJV . Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. Journal of Perinatology1997;17(6):455‐60. ">Modanlou 1997</a>; <a href="./references#CD000144-bbs2-0001" title="AinsworthSB , BeresfordMW , MilliganDW , ShawNJ , MatthewsJN , FentonAC , et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25‐29 weeks' gestation: a randomised trial. Lancet2000;355(9213):1387‐92. ">Ainsworth 2000</a>; <a href="./references#CD000144-bbs2-0008" title="KukkonenAK , VirtanenM , JarvenpaaAL , PokelaML , IkonenS , FellmanV . Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?. Acta Paediatrica2000;89(5):556‐61. ">Kukkonen 2000</a>). For the treatment trials, the meta‐analyses supported a significant increase in the risk of NEC (typical RR 1.37, 95% CI 1.04 to 1.81; typical RD 0.02, 95% CI 0.00 to 0.04, NNTH 50; 7 studies, 2616 infants). </p> <p>Overall, the meta‐analyses supported a significant increase in the risk of NEC associated with the use of animal derived surfactants (typical RR 1.38, 95% CI 1.08 to 1.76; typical RD 0.02, 95% CI 0.01 to 0.04; NNTH 50; 8 studies, 3462 infants). </p> </section> </section> <section id="CD000144-sec-0096"> <h5 class="title">Intraventricular hemorrhage (IVH) (Outcome 1.10):</h5> <section id="CD000144-sec-0097"> <h6 class="title">Prevention trials</h6> <p><a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> reported an increase in the risk of IVH associated with animal derived surfactant administration (RR 1.31, 95% CI 1.08 to 1.58; RD 0.09, 95% CI 0.03 to 0.15). <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> did not support an increased risk of IVH associated with prophylactic administration of either synthetic or animal derived surfactant (RR 0.99, 95% CI 0.86 to 1.15; RD 0.00, 95% CI ‐0.08 to 0.07). The meta‐analyses demonstrated a borderline significance increase in the risk of developing of IVH with the administration of animal derived surfactant (typical RR 1.13, 95% CI 1.00 to 1.27; typical RD 0.05, 95% CI 0.00 to 0.10; 2 studies, 1620 infants). </p> </section> <section id="CD000144-sec-0098"> <h6 class="title">Treatment trials</h6> <p>None of the six treatment trials that reported on IVH reported an effect of surfactant preparation on IVH. For the treatment trials, the meta‐analysis suggested no effect of surfactant preparation on the risk of IVH (typical RR 1.03, 95% CI 0.94 to 1.14; typical RD 0.01, 95% CI ‐0.02 to 0.04; 8 studies, 3425 infants). </p> <p>Overall, the meta‐analyses supported a marginal increase in the risk of IVH associated with animal derived surfactant extract treatment (typical RR 1.07, 95% CI 0.99 to 1.15; typical RD 0.02, 95% CI 0.00 to 0.05; 10 studies, 5045 infants). </p> </section> </section> <section id="CD000144-sec-0099"> <h5 class="title">Severe intraventricular hemorrhage (IVH) (Grades 3 or 4) (Outcome 1.11):</h5> <section id="CD000144-sec-0100"> <h6 class="title">Prevention trials</h6> <p><a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> reported no significant effect of surfactant preparation on the risk of severe IVH (RR 1.43, 95% CI 0.95 to 2.15; RD 0.04, 95% CI 0.00 to 0.08; 1 study, 853 infants). <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> did not stratify the data based on severity of IVH. </p> </section> <section id="CD000144-sec-0101"> <h6 class="title">Treatment trials</h6> <p>None of the seven trials that reported on the incidence of severe IVH noted an effect of surfactant preparation on the risk of severe IVH. For the treatment trials, no effect of surfactant preparation on the risk of severe IVH was noted (typical RR 1.02, 95% CI 0.85 to 1.21; typical RD 0.00, 95% CI ‐0.02 to 0.02; 8 studies, 3388 infants). </p> <p>Overall, the meta‐analyses supported no significant effect of surfactant preparation on the risk of severe IVH (typical RR 1.08, 95% CI 0.91 to 1.27; typical RD 0.01, 95% CI ‐0.01 to 0.03; 9 studies, 4241 infants). </p> </section> </section> <section id="CD000144-sec-0102"> <h5 class="title">Retinopathy of prematurity (ROP) (Outcome 1.12):</h5> <section id="CD000144-sec-0103"> <h6 class="title">Prevention trials</h6> <p><a href="./references#CD000144-bbs2-0007" title="HudakML , MartinDJ , EganEA , MattesonEJ , CummingsNJ , JungAL , et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics1997;100(1):39‐50. ">Hudak 1997</a> reported no significant effect of surfactant preparation on the risk of ROP (RR 0.96, 95% CI 0.87 to 1.06; RD ‐0.03, 95% CI ‐0.09 to 0.04). There was no significant difference between the animal derived surfactant and synthetic surfactant groups with respect to ROP in <a href="./references#CD000144-bbs2-0011" title="MoyaF , SinhaS , GadzinowskiJ , D'AgostinoR , SegalR , GuardiaC , et al. One‐year follow‐up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics2007;119(6):e1361‐70. MoyaFR , GadzinowskiJ , BancalariE , SalinasV , KopelmanB , BancalariA , et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics2005;115(4):1018‐29. ">Moya 2005</a> (RR 0.93, 95% CI 0.72 to 1.20; RD ‐0.02, 95% CI ‐0.08 to 0.05). Meta‐analyses of the trials that used prophylactic surfactant administration did not demonstrate any difference in the risk of ROP (typical RR 0.95, 95% CI 0.86 to 1.05; typical RD ‐0.02, 95% ‐0.07 to 0.02; 2 studies, 1613 infants). </p> </section> <section id="CD000144-sec-0104"> <h6 class="title">Treatment trials</h6> <p>None of the three trials that reported on ROP noted an association with surfactant preparation. The meta‐analysis of treatment trials demonstrated no effect of surfactant preparation on the risk of ROP (typical RR 0.94, 95% CI 0.86 to 1.03; typical RD ‐0.03, 95% CI ‐0.08 to 0.02; 4 studies, 1589 infants). </p> <p>Overall, the meta‐analyses supported a trend toward decreased risk of ROP in infants receiving animal derived surfactants (typical RR 0.95, 95% CI 0.89 to 1.01; typical RD ‐0.03, 95% CI ‐0.06 to 0.01; 6 studies, 3202 infants). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000144-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000144-sec-0105"></div> <p>Non‐protein containing synthetic surfactants and animal derived surfactant extracts have both been proven to be effective in the prevention and treatment of RDS and have become widely available for clinical use (<a href="./references#CD000144-bbs2-0053" title="SollRF , McQueenMC . Respiratory distress syndrome. In: SinclairJC , BrackenMB editor(s). Effective Care of the Newborn Infant. Oxford: Oxford University Press, 1992:325‐58. ">Soll 1992</a>). Although clinical trials have demonstrated that both non‐protein containing synthetic surfactants and animal derived surfactant preparations are effective, comparison in animal models has suggested that there may be greater efficacy of animal derived surfactant products, perhaps due to the protein content of these surfactants (<a href="./references#CD000144-bbs2-0060" title="TooleyWH , ClementsJA , MuramatsuK , BrownCL , SchlueterMA . Lung function in prematurely delivered rabbits treated with a synthetic surfactant. American Review of Respiratory Disease1987;136(3):651‐6. ">Tooley 1987</a>). The randomized controlled trials that have been conducted comparing animal derived surfactant extract to non‐protein containing synthetic surfactant have universally demonstrated greater improvement in immediate need for ventilator support in infants who receive animal derived surfactant extracts (<a href="./references#CD000144-bbs2-0053" title="SollRF , McQueenMC . Respiratory distress syndrome. In: SinclairJC , BrackenMB editor(s). Effective Care of the Newborn Infant. Oxford: Oxford University Press, 1992:325‐58. ">Soll 1992</a>). </p> <p>The meta‐analyses support a significant decrease in the risk of pneumothorax (typical RR 0.65, 95% CI 0.55 to 0.77; typical RD ‐0.04, 95% CI ‐0.06 to ‐0.02; NNT 25; 11 studies, 5356 infants) and a marginal decrease in the risk of mortality (typical RR 0.89, 95% CI 0.79 to 0.99; typical RD ‐0.02, 95% CI ‐0.04 to ‐0.00; 13 studies, 5413 infants) associated with animal derived surfactant treatment. In addition, the meta‐analyses support a marginal decrease in the risk of BPD or mortality associated with the use of animal derived surfactant preparations (typical RR 0.95, 95% CI 0.91 to 1.00; typical RD ‐0.03, 95% CI ‐0.06 to 0.00). </p> <p>However, there is a trend toward an increased risk of IVH (typical RR 1.07, 95% CI 0.99 to 1.15; typical RD 0.02, 95% CI 0.00 to 0.05; 10 studies, 5045 infants) associated with animal derived surfactant extract treatment. The increased risk in overall IVH is not reflected in an increased risk of severe IVH (typical RR 1.08, 95% CI 0.91 to 1.27; typical RD 0.01, 95% CI ‐0.01 to 0.03; 9 studies, 4241 infants).This increased risk was noted in the initial randomized controlled trials and was thought to be related to changes in cerebral blood flow after surfactant administration (<a href="./references#CD000144-bbs2-0035" title="GunkelJH , BanksPL . Surfactant therapy and intracranial hemorrhage: review of the literature and results of new analyses. Pediatrics1993;92(6):775‐86. ">Gunkel 1993</a>). </p> <p>In this updated meta‐analysis, a concern regarding an increase in the risk of NEC is noted in association with animal derived surfactant treatment. However, this risk does not outweigh the more clinically important improvements seen in mortality. A rough estimate from these analyses project that for every 100 infants we treat with an animal derived product as opposed to a protein free synthetic product we see four fewer pneumothoraces, two fewer deaths but two additional cases of NEC and two additional cases of IVH of any grade. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD000144-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.1 Mortality." data-id="CD000144-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full#CD000144-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.2 Bronchopulmonary dysplasia." data-id="CD000144-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.2 Bronchopulmonary dysplasia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full#CD000144-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.3 Chronic lung disease." data-id="CD000144-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.3 Chronic lung disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full#CD000144-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.6 Pneumothorax." data-id="CD000144-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Animal derived surfactant extract versus protein free synthetic surfactant, outcome: 1.6 Pneumothorax. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/full#CD000144-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 1 Mortality." data-id="CD000144-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 2 Bronchopulmonary dysplasia." data-id="CD000144-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 2 Bronchopulmonary dysplasia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 3 Chronic lung disease." data-id="CD000144-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 3 Chronic lung disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 4 Bronchopulmonary dysplasia or death." data-id="CD000144-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 4 Bronchopulmonary dysplasia or death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 5 Chronic lung disease or death." data-id="CD000144-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 5 Chronic lung disease or death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 6 Pneumothorax." data-id="CD000144-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 6 Pneumothorax. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 7 Patent ductus arteriosus." data-id="CD000144-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 7 Patent ductus arteriosus. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 8 Sepsis." data-id="CD000144-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 8 Sepsis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 9 Necrotizing enterocolitis." data-id="CD000144-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 9 Necrotizing enterocolitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 10 Intraventricular hemorrhage." data-id="CD000144-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 10 Intraventricular hemorrhage. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 11 Severe intraventricular hemorrhage, Grades 3 or 4." data-id="CD000144-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 11 Severe intraventricular hemorrhage, Grades 3 or 4. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000144-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/urn:x-wiley:14651858:media:CD000144:CD000144-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_t/tCD000144-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 12 Retinopathy of prematurity." data-id="CD000144-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Animal derived surfactant extract versus protein free synthetic surfactant, Outcome 12 Retinopathy of prematurity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/media/CDSR/CD000144/image_n/nCD000144-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD000144-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Animal derived surfactant extract versus protein free synthetic surfactant</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.79, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Prophylactic surfactant administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Treatment of established RDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.75, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Bronchopulmonary dysplasia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Prophylactic surfactant administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.85, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Treatment of established RDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.93, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Chronic lung disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Prophylactic surfactant administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.89, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Treatment of established RDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Bronchopulmonary dysplasia or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.91, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Prophylactic surfactant administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.90, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Treatment of established RDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.88, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Chronic lung disease or death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.90, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Prophylactic surfactant administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.89, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Treatment of established RDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.86, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Pneumothorax <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.55, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Prophylactic surfactant administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.46, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Treatment of established RDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3743</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.53, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Patent ductus arteriosus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Prophylactic surfactant administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.85, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Treatment of established RDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.90, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Sepsis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.91, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Prophylactic surfactant administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.92, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Treatment of established RDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.85, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Necrotizing enterocolitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.08, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Prophylactic surfactant administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.83, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Treatment of established RDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.04, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Intraventricular hemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5045</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.99, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Prophylactic surfactant administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.00, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Treatment of established RDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.94, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Severe intraventricular hemorrhage, Grades 3 or 4 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.91, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Prophylactic surfactant administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.95, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Treatment of established RDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.85, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Retinopathy of prematurity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.89, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Prophylactic surfactant administration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.86, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Treatment of established RDS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1589</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.86, 1.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Animal derived surfactant extract versus protein free synthetic surfactant</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000144.pub3/references#CD000144-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000144.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000144-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000144-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000144-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD000144-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD000144-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD000144-note-0002">ภาษาไทย</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000144\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000144\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000144\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000144\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000144\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=FKeXZrqu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000144.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000144.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000144.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000144.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000144.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727229569"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000144.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727229573"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000144.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea6fafbf49365',t:'MTc0MDcyNzIyOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 